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BACKGROUND AND PURPOSE 
About 80 million international travellers from high income countries per year cross the 
borders of tropical countries and a lot will encounter travellers’ diarrhoea as its’ notoriety and 
various studies from the past suggest: Travellers’ diarrhoea (TD) affects up to 60% of persons 
during a two week stay in a high risk country such as India or Kenya (1, 2) as illustrated in 
Figure 1. It is an old disease formerly known predominantly among soldiers who appeared to 
suffer more from diarrhoea and dysentery than from injuries of war (3). Abundance of 
colloquial terms may be as frequent as the disease itself and the names usually bear regional 
or historical flags, to name a few: Montezumas’ Revenge, la venganza de Atahualpa, Delhi 
Belly, Cairo Two-Step... 
Besides incapacitating travellers abroad or shortly after return, early studies indicated that 
diarrhoea could persist for one month or longer in 0.9% of travellers (1, 4). More recently, 
Irritable Bowel Syndrome (IBS) has been described among 6 of 61 (10%) previously healthy 
U.S. students who had experienced TD in Mexico (5). Since this study was limited to a small 
number of young people in one single country a broader assessment of sequelae of TD is 
desired. 
IBS as one of over 20 functional gastrointestinal disorders (FGID) is characterized by a wide 
variety of persistent symptoms. Symptoms can be multiple and change over the time. In 
western societies up to 14 % meet any diagnostic criteria and IBS prevalence ranges from 3 to 
10% depending on region and diagnostic criteria (6-8). Symptoms include abdominal 
discomfort or pain associated with defecation or a change in bowel habit and with features of 
disordered defecation. In absence of any clear organic cause the pathogenesis of IBS is 
considered to be multi-factorial. Overlapping psychological factors, altered visceral pain 
perception and abnormal gastrointestinal motility or permeability have been postulated as 
predominant mechanisms (9). Altered interaction between the immune and neuroenteric 
system caused by chronic, low-grade mucosal inflammation may lead to visceral 
hypersensitivity. Infectious gastroenteritis is discussed to initiate this inflammatory response 
(9-11). Several studies suggest that recent gastroenteritis (such as TD) might be one of the 
strongest risk factors for developing postinfectious IBS (pIBS) (5, 12, 13). A strong 
association between TD and the subsequent developing of IBS may have important 
implications for public health strategies at preventing TD and for planning interventions to 
protect travellers at great length. Therefore we first need to know updated TD rates and 
secondly we can focus on it’s consequences, in this case IBS. Finally we will compare rates 
and risk factors found with previous data of travellers for a broader assessment of health 
impairments abroad.  
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SUMMARY 
Travellers’ diarrhoea (TD) is the most common disease contracted when visiting tropical 
destinations. Irritable Bowel Syndrome is characterized by a variety of persistent symptoms. 
Symptoms can be multiple and change over the time. In western societies prevalence ranges 
from 3 to 10%, depending on region and diagnostic criteria. Symptoms include abdominal 
discomfort or pain associated with defecation or a change in bowel habit and with features of 
disordered defecation. Recent gastroenteritis (such as travellers’ diarrhoea) might be one of the 
strongest risk factors for developing postinfectious Irritable Bowel Syndrome. Previous 
smaller studies have detected rates of 4 to 11% of Irritable Bowel Syndrome among travellers 
to low income countries. So far no survey investigated this risk in Europeans, none used the 
Rome III diagnostic criteria. 
Within the same cohort of travellers we first address TD attack and incidence rates and TD-
associated risk factors (chapter I), secondly we concentrate on IBS attack, incidence rates and 
risk factors (chapter II) and finally, we compare our prospective cohort study established in 
chapter I and II with a similar cohort and with a retrospective study design focusing on 
selected health problems abroad, diarrhoea included (chapter III). 
We performed a prospective cohort study including follow-up six months post travel to a high 
TD risk region (confer Figure 1). All study participants were recruited at the Zentrum für 
Reisemedizin of the University of Zurich. Inclusion and exclusion criteria were strictly 
defined. A self-administered first questionnaire (Q1) was to be collected at enrolment. A 
second questionnaire (Q2) was sent immediately post - travel. After six months travellers 
received the final questionnaire (Q3) to identify persistent gastrointestinal problems. We 
adopted the following case definitions for TD and IBS. TD consisted of 3 or more unformed 
stools per 24h with or without an additional symptom. The IBS diagnosis was based on the 
Rome III criteria. IBS positives got the opportunity to receive a first free counselling by the 
Division of Gastroenterology of the University Hospital of Zurich. 
Data were analyzed by statistical standard methods including descriptive analysis, incidence 
rates calculation, univariate and multivariate analysis, calculation of risk ratios (RR) and 95% 
confidence intervals, adjustment of confounding, multivariate analysis using logistic regression 
and sensitivity analyses to check on robustness of estimates.  
The study protocol has been approved by the Ethical Commission of the Canton of Zurich. 
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In chapter I we found the TD attack rate to be 34.4% (95%CI 32.6-36.1), the overall two-
weeks incidence 27.2% (95%CI 26.1-28.8). Among the 3100 recruited, 2800 could be 
investigated, resulting in a participation rate of 89.2%. The highest two-weeks incidence rates 
were found for West Africa (45.5%; 95%CI 37.6-53.5) and the Indian subcontinent (35.5%; 
95%CI 31.2-39.8). Median TD duration was 2 days (range 1-90). Multivariate logistic 
regression analysis for detecting the most prominent risk factors of TD showed that a 
resolved diarrhoeal episode experienced in the 4 months pre-travel (RR 2.04, 95%CI 1.59-
2.61), antidepressive comedication (RR 2.10; 95%CI 1.16-3.78), allergic asthma (RR 1.67; 
95%CI 1.10-2.54), and reporting TD-independent fever (RR 6.56; 95%CI 3.07-14.06) are all 
significant potential contributors. TD remains a frequent, usually self-limited travel disease. 
Patients with pre-travel diarrhoea more often develop TD while abroad. Other clinically 
relevant risk factors like allergic asthma in the patients’ history will need in future more 
detailed research. A French group (Benard et al.) for example suggested in absorption studies 
with chromium 51-labelled EDTA a permeability defect of the gastrointestinal tract in 
asthmatic patients, supporting the hypothesis of the so called “united mucosa” characterised 
by defects in the whole mucosa. 
Among 2476 study participants with follow-up (79.9%) 6 months post-travel of the initial 
cohort of chapter I resulted in 38 (1.5%) subjects with Irritable Bowel Syndrome (IBS) as 
described in chapter II. The date 6 months after return of the index travel was the study 
endpoint. The 6 months-IBS incidence rate was 1.5% (1.1-2.0 95% CI), the postinfectious 6 
months-IBS incidence rate 3.0% (1.9-4.2 95% CI). In a multivariate logistic regression analysis 
we found the following risk factors: Suffering from travellers’ diarrhoea abroad (RR 3.67; 95% 
CI 1.82-7.61), an adverse life event experienced within 12 months pre-travel (RR 3.11; 95%CI 
1.43-6.78), a diarrhoea episode experienced up to 4 months pre-travel (RR 2.74; 95%CI 1.34-
5.61). In a large population of Swiss travellers IBS had a lower incidence rate as compared to 
previous studies among international travellers and within community-based studies. 
Nevertheless IBS is an important long-term travel sequelae with its incidence rate similar to 
influenza, but with a different prognosis. Strategies targeted at risk-groups need to be 
developed including more IBS cases to allow detailed sub-group analyses. 
Chapter III gives an overview of selected and frequent health problems abroad. We compare 
two prospective cohort studies (the IBS cohort of chapter II; cohort A), a previous one of the 
Travel Health Centre Zurich research group (cohort B; years 1998 – 2000) and a retrospective 
Swiss dataset including ill-returned travellers with data collected from 2004 to 2005 and 
published in 2007.  
43% (cohort A) and 40% (cohort B) reported any illness abroad, most frequent were diarrhoea 
(attack rate A 34.4% and B 25.9%) and cold (A 10.2%; B 16.8%). 5.3% A and 10.1% B 
measured fever. In both cohorts travellers suffering from health problems abroad tended to be 
younger (RR age A (18-25 years) 1.53; 95%CI 1.12-2.09 and B (12-25 years) 1.12; 95%CI 
0.85-1.47), stayed longer abroad (RR weeks of stay A 1.27; 95%CI 1.20-1.36 and B 1.08; 
95%CI 1.05-1.11) and had more frequently visited the Indian subcontinent (RR A 1.79; 
95%CI 1.38-2.34 and B 2.07; 95%CI 1.36-3.16). Females reported significantly more 
constipation and insect stings, male travellers suffered more from fever. Within the 
retrospective dataset travel durations were shorter and visiting friends and relatives accounted 
for one third of the study population with a different risk pattern for infectious diseases when 
compared to the prospective cohorts. Fever and gastrointestinal diseases were also frequently 
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reported diseases among the retrospectively collected patients, but with lower acute diarrhoea 
rates among visiting friends and relatives. Whereas other illnesses such as malaria, sexually 
transmitted diseases and neglected tropical diseases (e.g. Leishmaniasis) formed together the 
biggest entity, such proportions were out of reach in cohort studies.  
Diarrhoea is a frequent infectious disease encountered abroad. In future we will need more 
specific risk group assessment for prevention and prophylactic interventions must be 
evaluated. 
 
Prospectively collected questionnaire–based results and data evaluated on the basis of MD 
diagnoses complement each another. Prospective cohort studies strengths’ is the exposure 
assessment. They summarise encountered health problems abroad, assess incidence rates and 
risk ratios in generally healthy travellers with pre- and post-travel exposure factors. Limiting 
factor is – if the study is questionnaire based – a reliable and accurate case definition and the 
further evaluation. Retrospective case series base on MD diagnosis, they focus on more 
serious or persistent health care problems after travel exposure. Their weakness is that the 
exposure assessment is often prone to bias. 
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GERMAN SUMMARY - ZUSAMMENFASSUNG 
 
Diese Studie hat primär zum Ziel, Charakteristika von Reisedurchfall (Kapitel I), des 
Reizdarm-Syndroms (Kapitel II) sowie die ausgewählten, häufigsten, generellen Reise-
krankheiten (Kapitel III) qualitativ und quantitativ zu beschreiben. In diesem letzten Schritt 
wurde die Primärstudie von Kapitel I und II, eine prospektive Kohortenstudie, mit einer ande-
ren ebenfalls prospektiven Kohortenstudie früherer Zeit und einer retrospektiven Schweizer 
GeoSentinel Studie verglichen. 
 Reisediarrhöe ist bei Erwachsenen die mit Abstand häufigste Gesundheitsstörung auf 
Reisen in subtropische und tropische Destinationen. Reisediarrhöe, definiert als ! 3 
ungeformte Stuhlgänge pro 24 Stunden, wird oft begleitet von Symptomen wie Spasmen, 
Meteorismus, Nausea, Fieber, plötzlichem Stuhldrang, Erbrechen und Blut oder Schleim im 
Stuhl; Verursacher sind fäkal-oral übertragene Bakterien, Viren oder Parasiten. Reisediarrhöe 
schränkt die Mobilität erheblich ein, ist jedoch selten lebensbedrohlich. In den meisten Fällen 
heilt sie spontan nach etwa 4 Tagen. Bei einer Minderheit können allerdings Symptome 
anhalten und eine chronisch - fluktuierende Folgeerkrankung auslösen: das Reizdarm-
syndrom. 
 Das Reizdarmsyndrom gehört zu den häufigsten funktionellen Magen-Darm-
Erkrankungen. Es definiert sich durch regelmässige Abdominalschmerzen und Änderung der 
Stuhlgewohnheiten. Die Diagnosegrundlage stellen die Rome III Kriterien (Rome 
Foundation, Prof. Dr. med. D. A. Drossman, Begründer) dar. 
Ein Schwerpunkt dieser Studie liegt bei der Evaluation des potentiellen Zusammenhangs von 
Reisedurchfall und nachfolgend auftretendem Reizdarm-Syndrom. In der Literatur ist 
bekannt, dass Enteropathogene eine initiierende Rolle bei chronischen Darmerkrankungen 
innehaben. In vorhergehenden Studien mit Reisenden waren die Stichprobenzahlen klein. 
Zum Themenkomplex, der durch Infektionen verursachten chronischen Erkrankungen, wird 
mit diesem breit angelegten Forschungsprojekt ein wichtiger Beitrag geliefert, wobei 
Risikogruppen identifiziert und neue Strategien in der Prävention evaluiert werden können.  
 
Eine Kohorte von Reisenden wird prospektiv mittels Fragebogen vor, während und einmal 
nach der Reise befragt. Insgesamt sollen ca. 2500 Reisende rekrutiert werden. Neuerkrankten 
(mit vermutetem Reizdarmsyndrom) wird eine unentgeltliche Beratung in der 
Gastroenterologie des Universitätsspitals Zürichs angeboten. Um die Antwortquote zu 
erhöhen, wird eine kleine Verlosung von Reisegutscheinen am Ende der Studie durchgeführt. 
Fragebögen umfassen standardisierte Fragen, gemäss den Rome III-Kriterien für Reizdarm. 
Geschlossene, strukturierte Fragen zur Demografie, zu reise-, verhaltens- und gesund-
heitsbezogenen Faktoren in Anlehnung an den staatlichen Schweizerischen Gesundheits-
fragebogen und erprobten Reisediarrhöestudien sind ebenfalls Teil der Forschungsstudie. 
Datenauswertung. Die erfassten Faktoren werden qualitativ und quantitativ beschrieben. 
Inzidenzraten und 95% Konfidenzintervalle werden berechnet. Multiple Regressionsmodelle 
werden eingesetzt, um den Zusammenhang zwischen Reisedurchfall und Reizdarm zu 
evaluieren. Zwecks Prüfung der Daten-Validität werden Sensitvitätstests und weitere Daten-
quellen herangezogen. 
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Ethische Aspekte. Es wird keine Intervention durchgeführt, denn die Datenerhebung beruht 
ausschliesslich auf einer Umfrage mittels Fragebogen. Die Auswertung der Daten erfolgt 
anonymisiert. Persönliche Daten und retournierte Fragebögen werden separat und unter 
Verschluss aufbewahrt. 
 
Kapitel I beinhaltet Inzidenz-Raten und Risikofaktoren von Reisediarrhöe. Mittels der oben 
genannten Methodik konnte gezeigt werden, dass unter einer Teilnahmerate von 81.9% unter 
2800 Gereisten die Befallrate von Reisedurchfall 34.4% und die mittlere 2-Wochen-Inzidenz 
27.2% beträgt. Höchste Inzidenzraten sind für den indischen Subkontinent gefunden worden 
(35.5%) und Westafrika (45.5%). Signifikante Risikofaktoren resultierend aus einer 
Multivariaten Analyse ergeben sich aus einer durchgemachten Diarrhöe-Episode bis 4 Monate 
vor der Abreise (Risikorate RR 2.04; 95% CI 1.59-2.61), Antidepressiva als Co-Medikation 
(RR 2.10; 95% CI 1.16-3.78), allergischem Asthma (RR 1.67; 95%CI 1.10-2.54) und aus 
einer Fiebererkrankung auf Reise (RR 6.56; 95%CI 3.07-14.06), die nicht im Zusammenhang 
steht mit Fieber als Begleitsymptom von Reisedurchfall. Demzufolge bleibt Reisedurchfall 
eine der häufigsten Reiseerkrankungen. 
Kapitel II umkreist die eigentliche Fragestellung, ob Reisediarrhöe zu Reizdarmsyndrom 
führt, beantwortet in welchem Umfang Reisende davon betroffen sind und welche Risken 
letztlich zu Reizdarm führen könnten. Bei einer Teilnahmerate von 79.9% sind 38 (1.5%) 
Personen von 2476 Gereisten an Reizdarmsyndrom erkrankt, dabei beträgt die 6-Monats-
Inzidenz 1.5% (95% Konfidenzintervall 1.1-2.0), die postinfektiöse Reizdarmsyndrom 6-
Monats-Inzidenz hingegen 3.0% (1.9 – 4.2 95% CI). Als potentielle Risiken, die zu diesen 
Langzeitfolgen führen, wurden in unserer Multivariatenanalyse unter allen möglichen 
erfassten Variablen primär Reisediarrhöe (3.67; 95%CI 1.82-7.61), gefolgt von einem 
negativen, einschneidenden Lebensereignis (RR 3.11; 95%CI 1.43-6.78) gefunden. Auch eine 
durchgemachte, kurze Diarrhöepisode vor Abreise (RR 2.74; 95%CI 1.43-6.78) taucht wieder 
als möglicher Co-Faktor, verantwortlich für die Entstehung von Reizdarmsyndrom, auf. In 
dieser breiten Schweizer Studienpopulation haben wir eine tiefere IBS Inzidenzrate von 1% 
gefunden, verglichen zu anderen Raten von Reisenden von 4-11%, sowie anderen 
bevölkerungsbasierten Studien mit Nicht-Reisenden. Dennoch ist IBS ein relevantes, 
nachhaltiges „Reiseandenken“ dessen Inzidenzrate sich der von der Grippe (Influenza) 
angleicht, wenngleich mit einem deutlich anderen Krankheitsverlauf. Unsere Vision wäre es, 
Präventionsstrategien an Risikogruppen angepasst zu entwickeln, fussend auch auf Studien 
mit mehr IBS Fällen für eingehendere Untergruppenanalysen. 
In Kapitel III wird diese prospektiven Kohortenstudie A mit einer im Aufbau und Design 
ähnlichen, früheren Studie B der Forschungsgruppe des Zentrums für Reisemedizin Zürich 
verglichen, unter dem Aspekt der häufigsten Krankheiten oder Infekte auf Reise. Aus diesem 
primären Vergleich sind keine signifikanten Unterschiede zwischen den beiden Studien 
festgestellt worden. Zudem werden die beiden Studien mit einer retrospektiven, Schweizer 
GeoSentinel Studie verglichen. GeoSentinel Kliniken gehören einem globalen Netzwerk mit 
einer ärztebasierten Datenbankerfassung von verschiedensten Krankheitsdiagnosen. Die 
beiden Kohortenstudien weisen ein gemeinsames demographisches und reisecharakte-
ristisches Muster auf. GeoSentinel Schweiz enthaltet generell kürzere Reisedauer und ein 
drittel der Studienpopulation sind Reisende, welche ihre Familien und Freunde in den (Sub-) 
Tropen besuchen (Visiting Friends and Relatives). Besondere Beachtung wird auch Gender–
Unterschieden geschenkt. Eine Rangliste der häufigsten, berichteten Infektionskrankheiten 
von Reisenden ist erstellt worden: Diarrhöe (Befallsrate A 34.4%; B 25.9%) gefolgt von 
Erkältungen (A 10.2%; B 16.8%) und Fieber (A 5.3%; B 10.1%) sind die häufigsten 
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Beeinträchtigungen. Reisende, welche über irgendein Gesundheitsproblem auswärts 
berichteten, waren tendenziell jünger (RR 18-25jährige Altersgruppe der Studie A 1.53; 
95%CI 1.12-2.08 und 12-25jährige Altersgruppe der Studie B 1.12; 95%CI 0.85-1.47), sie 
reisten länger (RR kontinuierliche Reisewochen A 1.27; 95%CI 1.20-1.36 und B 1.05; 95%CI 
1.05-1.11) und sie hatten öfters den indischen Subkontinent besucht (RR A 1.79; 95%CI 1.38-
2.36 und B 2.07; 95%CI 1.36-3.16). Frauen litten mehr unter Verstopfung und 
Insektenstichen, Männer erkrankten häufiger an Fieber. Diese Zahlen ergänzen sich zu den 
GeoSentinel Daten, letztere mit allerdings mehr Besucher von Freunde und Familie (VFR), 
welche ein anderes Risikoprofil für Infektionskrankheiten aufweisen. Interessanterweise 
haben wir festgestellt, dass etwa 8% (Studie A, B und andere von Hill et. al.) einen Arzt auf 
Reise aufsuchen, was die Interpretation erlaubt, dass reisemedizinisch beratene Touristen, 
Geschäftsreisende und die Besucher ihrer Familien und Freunde mit Impfstatus auf neustem 
Stand zum Grossteil weniger auf Arztbesuche angewiesen sind, ausser wenn Fieber oder 
schwere Symptome auftreten (Beispiel Malaria-Ausschluss). Diarrhöe war in jedem 
Studienfall häufig. In Zukunft braucht es ein genaueres Erfassen spezieller Risikogruppen und 
die Evaluation prophylaktischer Interventionen.  
 
Prospektiv gesammelte Fragebogendaten haben den Vorteil, dass man vor und nach der Reise 
evaluiert, der Expositionsfaktor spielt die Hauptrolle, die Falldefinitionen müssen zuverlässig 
formuliert werden. Prospektive Studien geben eine Übersicht, man berechnet aus selbst-
rapportierten Fragebögen Inzidenzen und Risikoraten aus einer Population von meist 
Gesunden. Retrospektives Studiendesign basiert auf meist Arztdiagnosen, die Erfassung des 
Expositionsfaktor kann verzerrt sein. Retrospektive Daten von Kliniken fokussieren mehr auf 
schlimmere oder persistierende Fälle und summieren Malaria, sexuell übertragene 
Krankheiten und seltene Tropenkrankheiten (Neglected Tropical Diseases) auf. 
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CHAPTER I 
 
Diarrhoea in a Large Prospective Cohort of European Travellers to 
Resource-Limited Destinations  
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 ABSTRACT 
 
Background. Risk factors of travellers’ diarrhoea (TD) are insufficiently known, incidence 
rates need to be updated. 
Methods. Between July 2006 and January 2008 adult customers of our Travel Health Centre 
leaving to a low income country for a duration of 1 to 8 weeks were invited to participate in a 
prospective cohort study. They received one questionnaire pre- and a second one immediately 
post-travel. Two-week incidence rates were calculated for TD episodes, risk assessment 
included demographic and travel-related variables, medical history and behavioural factors. 
Results. Among the 3100 recruited, 2800 could be investigated, resulting in a participation 
rate of 89.2%. The TD attack rate was 34.4% (95%CI 32.6-36.1), the overall two-weeks 
incidence 27.2% (95%CI 26.1-28.8). The highest two-weeks incidence rates were found for 
West Africa (45.5%, 95%CI 37.6-53.5) and the Indian subcontinent (35.5%, 95%CI 31.2-
39.8). Median TD duration was 2 days (range 1-90). The majority treated TD with loperamide 
(57.6%), while minorities used probiotics (23.0%) and antibiotics (6.8%). Multivariate 
logistic regression analysis showed that a resolved diarrhoeal episode experienced in the 4 
months pre-travel (RR 2.04, 95%CI 1.59-2.61), antidepressive comedication (RR 2.10, 
95%CI 1.16-3.78), allergic asthma (RR 1.67, 95%CI 1.10-2.54), and reporting TD-
independent fever (RR 6.56, 95%CI 3.07-14.06) were the most prominent risk factors of TD. 
Conclusions. TD remains a frequent, usually self-limited travel disease. Patients with pre-
travel diarrhoea more often develop TD while abroad. Risk factors like allergic asthma in the 
patients’ history and TD-independent fever will need further investigation. 
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INTRODUCTION 
Travellers’ diarrhoea (TD), the most common health problem in visitors to tropical and 
subtropical destinations, affects between 20 to over 60% of persons during a two weeks stay 
in a high risk country such as India or Kenya (1, 2, 14). As many of those data have been 
generated some decades ago, the aim of this study is to provide updated region-based TD 
incidences, to investigate risk factors, and to survey actual treatment options used. 
 
METHODS 
Study design. Basing on a protocol approved by the Ethical Commission of the Canton of 
Zurich, we have performed a prospective questionnaire-based cohort study. 
Study population. Potential participants were recruited at the Centre for Travel Health of the 
University of Zurich between July 2006 and January 2008. To be included, participants had to 
be at least 18 year-old German-speaking Swiss residents who planned to travel to high-risk 
TD destinations (1, 15) for a duration of 1 to 8 weeks. Subjects planning to take prophylactic 
antibiotics during their trip, those who reported a history of severe illness (anemia, cancer, 
immunodeficiency or immunosuppressive disorders, severe psychiatric illness, previous 
gastrointestinal surgery), functional organic gastrointestinal disorders (according to Rome II 
(16)/ Rome III (17) criteria), recurring diarrhoeal symptoms within a four months pre-travel 
period, and pregnant women were excluded.  
Definitions. Basing on the UNICEF/WHO definition, TD was defined as three or more 
unformed stools per 24 h with or without at least one accompanying symptom (nausea, 
vomiting, abdominal cramps, tenesmus, fever, blood in stools)(18, 19), while 3 or more 
unformed stools with additional symptom are named classic TD (20, 21). Patients with one or 
two loose stools per 24 h abroad had mild diarrhoea (19, 21). Only TD was used for incidence 
calculations and for multivariate analysis. Those who reported fever or blood in their TD 
stools were rated as dysentery. Multiple episodes of TD had to be separated by a TD-free 
interval of at least 72 hours. Incapacitation meant an inability to pursue planned travel 
activities and it was rated in 3 subgroups; severe was defined by being confined to bed for at 
least 12 hours or by consulting a doctor (15, 20). Body Mass Index (BMI) was calculated 
from participants’ height and weight data at enrolment. Countries and subcontinents were 
grouped according to the United Nations World Migrant Stock (22). Comedication and 
diseases were classified by main categories of the International Classification of Diseases 
(ICD-10 2007)(23). 
Study conduct. Participants who visited our Centre for Travel Health for standard pre-travel 
consultation were invited to participate in the study on a voluntary basis. Upon signing an 
informed consent, they received two questionnaires. Q1 was collected immediately upon 
completion, while Q2 was to be returned in the first week after return reminded by mail or 
email; Q2 was similar to a diary. During the pre-travel consultation the volunteers also 
obtained standard information about TD risks, options for prevention and for self-therapy, and 
guidance on when it is advisable to consult a physician for TD. 
Q1 included 30-structured questions to assess the itinerary, previous travel to the 
tropics, demographic data, the body mass index, chronic diseases, confirmed allergies, and 
pre-travel diarrhoea characteristics. Also adverse life events in the preceding 12 months, self-
reported stress, smoking habits and alcohol consumption, and perceived susceptibility to 
diarrhoea were investigated.  
Q2 consisted of 17-questions to confirm the travel itinerary and to document a detailed 
history of TD abroad, including TD medication used. After an initial trial phase of three 
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months we added questions about syndromes abroad (also including the number of TD 
episodes) and about attitudes towards diarrhoea (24, 25). Non-responders were reminded by 
mail twice; patients reporting uncured diarrhoea were followed until resolution. Those who 
refused to respond to Q2 were interviewed with the single question whether they had 
experienced diarrhoea while abroad. No stool samples were collected in this study. 
Statistical analysis. Data were analyzed using Stata statistical software, version 10.1 (Stata). 
To calculate the average two-weeks incidences in various subcontinents we considered all the 
reported number of TD episodes reported and accounted for any two weeks of stay. The 95% 
confidence intervals (CI) for the incidence rates in various subcontinent were estimated as per 
Newcombe (26). We calculated also the first two weeks of stay testing for sensitivity. 
We compared differences in proportions of demographics, attitudes and clinical variables by 
the chi square and Wilcoxon rank sum tests. The significance level was set at ! (alpha) = 
0.05. All travel- and traveller-related risk factors were evaluated as independent potential risk 
factors for the development of TD in a multivariate logistic regression model. Relative risks 
(RR) were determined by stepwise procedure. Questions inserted later (such as e.g. perceived 
susceptibility towards diarrhoea and tap water consumption) were analyzed by imputing 
missing values using gender, destination continent and education for the multivariate analysis. 
As sensitivity test for the multivariate analysis we compared first the complete dataset with a 
selection of half of the data. Second, we used the classic TD definition as outcome.  




Demographics. Among 3100 enrolled travellers 2800 (90.3%) were eligible for analysis 
(figure 1). Gender was approximately equally distributed (Table 1). Mean age was 38.8 ± 12.6 
years (median 35) and half of the population (1403, 51.1%) had a university degree, with 
significant higher proportions among the business travellers (p = 0.0057).  Mean travel 
duration was 3.2 weeks with the most frequently visited destinations being Southeast (SE) 
Asia (636, 22.7%), followed by East Africa (522, 18.6%), the Indian subcontinent (476, 
17.0%) and South America (435,15.5%). The two-weeks TD incidence for various regions is 
shown in figure 2 with the highest rates reported in most parts of Africa and on the Indian 
subcontinent. The largest group of travellers were tourists (1539; 87.9%), while 121 (10.8%) 
went for business. Latter had a median travel time of 2 weeks , but 90 (5.1%) visiting friends 
and relatives (VFR) and tourists travelled for a median duration of 3 weeks. A significantly 
higher proportion of businessmen visited the Indian subcontinent (44; 15.3%, p = 0.0000) and 
was male (69; 57.0%, p = 0.0132). Africa was the preferred continent of tourists (508, 
33.1%), while VFR mainly travelled to Latin America (38; 42.2%) and Asia (22; 24.4%).  A 
minority visited the tropics or subtropics for the first time (208, 7.5%), among whom 92 
(44.2%) rated themselves as intermediate to very susceptible to diarrhoea, compared to 940 
(36.7%) among experienced travellers. Post-travel questionnaires were returned within a 
median of 10 days (interquartile range 2-30) after returning home. 
Among other diseases (596; 25.8%), common cold (277, 9.9%) and headache (106; 
3.8%) were most often mentioned. Fever independent from TD was mentioned by 45 (2.5%) 
study participants. 
Travellers’ diarrhoea. The TD attack rate among the 962 patients for the varying duration of 
stay abroad was 34.4 % (95% CI 32.6-36.1) and the worldwide TD incidence for any two-
weeks stay 27.2% (95% CI 26.1-28.8). The incidence for the first two weeks was 26.5% (95% 
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CI 23.7-29.2). The majority (573 (59.6%) reported a single TD episode, 248 (30.2%) suffered 
from more than one episode while abroad. The number of TD episodes experienced increased 
approximately linearly with the duration of stay as illustrated in figure 3. A total of 785 
suffered of classic TD while abroad (28.0%; 95%CI 26.4-29.7) and 303 (10.8%) experienced 
mild diarrhoea. The most frequent accompanying symptoms were tenesmus (56.0%) and 
cramps (49.2%). Fever (mean 38.4 ± 0.8 °C) or vomiting accounted for about 15% each (146 
with fever, 136 vomiting), and 166 (17.3%) study subjects suffered from dysentery. The three 
top 2 weeks incidence rates for dysentery were recorded in Middle and in Western Africa, and 
on the Indian subcontinent (figure 2).  
All characteristics of diarrhoea of the index travel are summarised in table 3. TD 
patients reporting treatment with loperamide (antibiotics excluded) were found to have more 
TD episodes (RR 1.45, 95% CI 1.05-2.19, p=0.0026). In contrast, antibiotic or probiotic use 
for TD had no significant influence on the number of TD episodes reported (p=0.282, p 
=0.532, respectively). 
TD occurred on average within 2.1 weeks after arrival (median 2 days) and patients 
counted on average 4 stools per day. One of nine (111, 11.5%) experienced diarrhoea for 
longer than one week, with 37 (3.8%) individuals suffering from persistent and 11 (1.1%) 
from chronic diarrhoea. Roughly two thirds of the patients (614, 65.0%) could pursue their 
planned activities, but 102 (10.8%) were confined to bed or consulted a physician.  
Among treated patients, 343 (57.6%) chose an antimotility agent for self-medication of TD, 
137 (23.0%) a probiotic and 51 combined both .116 (12.3%) TD patients reported any intake 
of antibiotics, 65 of them (56.0%) for diarrhoea.  Most frequently used antibiotics against TD 
were quinolones (e.g. ciprofloxacin 25), but also trimethoprim-sulfamethoxazole (6 cases). 
The use of charcoal was reported by 70 persons (19.5%). Oral rehydratation therapy was 
mentioned in 62 (6.4%) of the TD subjects and in 16 (9.6%) of dysenteric subjects. Among 
the dysentery cases, 35 (21.1%) were treated with an antibiotic, 79 (47.6%) used exclusively 
non-antibiotic medication, mostly loperamide (n = 38). Against medical advice, 152 (58.7%; 
p= 0.0191) travellers with an academic background reported consumption of tap water, 60 
(39.5%) of those developed TD. Health characteristics and some preventive attitudes are 
reported in table 2. 
Factors influencing TD. Table 4 shows risk factors independently associated with TD with 
increasing age being the only protective one. We found significant associations neither with 
other reported allergies (e.g. hay fever, atopic dermatitis), nor with other pre-travel co-
medications (e.g. hormonal). Seasonality was not linked to TD.  
 
DISCUSSION 
In view of the fact that TD incidence has been reduced in some countries such as Jamaica (27) 
and Thailand (28), updated worldwide regional incidence data were long due. For most 
regions they stay in the same order of magnitude (19, 29), particularly if we consider that here 
TD rates are presented in contrast to classic TD rates in most previous surveys (1, 2, 30). 
Using the classic TD definition we detected no significantly different attack rates or risk 
factors. Only East Asia, including China, and to a lesser degree also Latin America, showed a 
marked decrease. Known high-risk TD destinations such as the Middle East, North Africa and 
the Caribbean are in our study underrepresented, since visitors to those destinations generally 
do not consider a pre-travel consultation as indicated (31). Younger age and longer duration 
of travel are well known TD risk factors. In contrast, neither smoking, consuming alcohol nor 
gender influenced the occurrence of TD significantly. TD cases, who previously had 
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experienced TD, reported a significantly higher susceptibility to diarrhoea (p=0.0127); that 
may be associated with genetic factors (32, 33).  
Allergic asthma, mental/behavioural co-medication, a high BMI, and a TD-
independent fever episode to our knowledge have so far never been considered risk factors for 
TD. Such findings, however, may be clinically relevant and enhanced preventive measures to 
protect travellers vulnerable to multiple health impairments abroad should be considered. 
Allergic asthma as risk factor needs further exploration (34, 35), but in contrast, both atopy 
and hay fever did not influence TD in our cohort. Within psychiatric co-medication, mainly 
antidepressants might be associated with diarrhoea as a side-effect (36, 37), also the 
hypothalamic-pituary-adrenal axis might play a role (38). An elevated BMI resulted in a 
marginally increased risk ratio. A high BMI also is a predisposing factor for community-
based diarrhoea (39-41). Obese people have a higher food intake, they may thus consume a 
larger inoculum of pathogens. Lastly, a fever episode independent from TD is suggestive for 
some low-grade inflammatory and/or immunological process (9, 42).  
Loperamide was widely used to treat TD in our cohort, which is consistent with other 
reports (19, 43) and some of the guidelines (44, 45). Only a minority of 6.8% of all cases 
relied on an antibiotic for TD, which in most cases was carried in their travel medical kit. 
Almost 10% turned to a local pharmacy, potentially exposing themselves to the risk of fake 
medication abroad or inadequate storage temperatures (46, 47).  
Our study design with inherent selection bias (48) and missing chronology of TD 
treatment does not allow an evaluation of the various treatment schedules. However, patients 
without antibiotic TD treatment (mostly they used loperamide) were found to have 
significantly more TD episodes.  
Half of our study population had an university degree, travelling mostly as tourists but 
also for business. They might spend more money for travels and be likely to ask for pre-travel 
medical advice.  Hence, our results, although not ideal with respect to behaviour, may reflect 
a rather high socio-economic stratum. As our study participants all got the usual advice on 
hygiene measures to prevent TD, and as many were non compliant these approaches have to 
be improved, or other means of prophylaxis must be used. For instance, we can increase the 
public and tourism industry demand to food safety to reduce the burden of TD among 
travellers (49).  
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Table 2. Health characteristics and TD-preventive attitudes abroad (N = 2800). 
   Total
1)
  subgroups  p value
2)
 
  TD 
 
n = 962 
no diarrhoea 
abroad 
n = 1535 
 
Body Mass Index n = 2789   0.3414 
 < 18.5 91 (3.3) 32 (35.2) 50 (54.9) Reference 
 18.5-29.9 2612 (93.7) 892 (34.2) 1437 (55.0) Reference 













 allergic asthma 110 (17.5) 50 (45.5) 49 (44.5) 0.0124 
Comedication
3)
 n = 2800    
 mental / behavioural
 4)
 52 (16.8) 25 (23.6) 22 (13.3) 0.0348 
History of diarrhoea n = 1843 n = 674 n = 954  
 TD ever experienced 955 (51.8) 377 (39.5) 468 (49.0) 0.0295 
History of TD incapacitation n = 1029 n = 373 n = 497  
 low 528 (51.3) 197 (37.3) 266 (50.4) Reference 
 intermediate to severe 501 (48.7) 215 (42.9) 231 (46.1) 0.0049 
Subjective diarrhoea susceptibility n = 1656 n = 584 n = 886  
 low 617 (37.3) 186 (30.1) 377 (61.1) Reference 
 intermediate 974 (58.8) 363 (37.3) 486 (49.9) Reference 
 high 65 (3.9) 35 (53.8) 23 (35.4) 0.0011 
Diarrhoea episode  
 < 4 months before index travel5) 
n = 2800 
347 (12.4) 
n = 960 
172 (49.6) 





 n = 2323 n = 792 n = 1279  
  Buffet meals 2190 (94.3) 742 (33.9) 1214 (55.4) 0.2346 
  Private / family meals 982 (42.3) 374 (38.1) 465 (47.4) 0.0027 
  Street vendors meals 882 (38.0) 310 (35.1) 474 (53.7) 0.3316 








NOTE. p < 0.05 was considered statistically significant. NS, not significant 
1) 








 Multiple answers possible  
4)
 Mainly antidepressive (n=49)  
5)
 Pre-existing FGID (Functional Gastrointestinal Disease) patients and subjects with diarrhoea unresolved or 
lasting ! 14d within this diarrhoea episode < 4 months before index travel were excluded as defined in exclusion 
criteria 
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Table 4. Risk factors for developing TD  
   in a multivariate logistic regression analysis controlled for gender (N = 2565).  
Significant risk factors among all reported variables.  
 
Variable Risk Ratio 95% CI p 
Gender 0.96 0.80-1.15 0.651 
TD independent fever 6.56 3.06-14.04 0.000 
Psychiatric comedication  2.11 1.17-3.80 0.013 
Diarrhoea pre-travel 2.03 1.59-2.54 0.000 
Allergic asthma 1.67 1.10-2.54 0.018 
Malaria chemoprophylaxis 1.38 1.12-1.70 0.002 
Travel duration 1.28 1.21-1.35 0.000 
Body Mass Index 1.04 1.01-1.08 0.004 
Age 0.98 0.98-.99 0.000 
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LEGENDS FOR FIGURES 
 
Figure 1. Overview of prospective participants recruitment. 
1) 





Figure 2. Two weeks incidences for TD and dysentery in selected areas. (N = 2794) 
Blue (dark in black & white) are 2 weeks incidences for TD (n=962) 
Below red (grey in black & white) are 2 weeks incidences for dysentery (n=166) 
Pinned subcontinents have TD rates over 35.0 and dysentery rates over 5.0 
 
 
Figure 3. Number of TD episodes by weeks of stay at a high-risk region. (n=821) 
1) 1 episode (n= 573). Median 3 (1-8), mean 3.4 ± 1.7 weeks 
2) 2 episodes (!72h-interval) (n=189). Median 3.5 (1-8), mean 4.1 ± 2.0 weeks 
3) 3 episodes (!72h-interval) (n=51). Median 4 (2-8), mean 4.4 ± 2.0 weeks 
4) 4 episodes (!72h-interval) (n=8). Median 6 (2-8), mean 5.9 ± 2.0 weeks 
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Background and aim. Travellers’ diarrhoea (TD) remains the most frequent travel-
associated infection. In various exposure settings between 3 and 36% of enteric infections 
were followed by a postinfectious irritable bowel syndrome (pIBS). Travel-related incidence 
rates of IBS base on small studies and its risk factors have been insufficiently evaluated. 
 
Methods. In a prospective questionnaire-based cohort study adult travellers to resource-
limited destinations were enrolled. Demographics, travel characteristics and medical history 
were assessed; those with functional or organic gastrointestinal disorders were excluded. 
Immediately after return, the volunteers completed a second questionnaire on TD, other 
health impairments, and on their food hygiene-related practices abroad. Six months post-
travel IBS basing on Rome III criteria was assessed in a follow-up questionnaire. Risk factors 
were analyzed by multivariate logistic regression.  
 
Findings. Among a total of 2476 subjects analysed (participation rate 72.4%), 38 (1.5%) 
newly developed IBS, and a 6-months-incidence rate for pIBS of 3.0% (95%CI 1.9-4.2) was 
recorded in TD patients. Significant risk factors were TD during the surveyed journey (RR 
3.67; 95% 1.82-7.40), an adverse life event experienced within 12 months pre-travel (RR 
3.11; 1.40-6.78), and a diarrhoeal episode experienced up to 4 months pre-travel (RR 2.74; 
95%CI 1.34-5.61). The risk of acquiring IBS was up to sixfold increased following multiple 
diarrhoeal episodes. 
 
Interpretation. In a large population of European travellers IBS had a lower incidence rate as 
compared to previous studies. Nevertheless this is a relevant long-term travel sequelae, 
requiring strategies targeted at risk-groups.  
 
Funding. The study was self-funded by the Division of Communicable Diseases at the 
Institute of Social and Preventive Medicine of the University of Zurich. 
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INTRODUCTION 
 
Irritable bowel syndrome (IBS) is characterized by relapsing and fluctuating gastrointestinal 
symptoms, including abdominal pain, discomfort and changed bowel habits (50). The 
diagnosis bases on the exclusion of other functional or organic disorders and the Rome I, II 
and at last III criteria (51). The pathogenesis of IBS is multifaceted: genetic (52)  epigenetic 
(53, 54), environmental (55), central nervous system and psychological characteristics (13, 
56), e.g. coping with stress, have been postulated. A worldwide prevalence of 10 to 15% (57, 
58) and an annual incidence of 0.2 to 7% (59, 60) were reported. Various studies indicated 
that an episode of acute gastroenteritis, such as travellers’ diarrhoea, was an important risk 
factor for developing postinfectious IBS (pIBS) (9). In a meta analysis of eighteen studies 
pIBS incidence rates ranged from 4 to 32%; a pooled OR for developing pIBS 6 months post 
diarrhoea was 5.18 (95% CI 3.24-8.26) (7) respectively 7.3 (95% CI, 4.7-11.1) (61). 
Underlying host-related factors combined with a gastrointestinal infection appeared to induce 
persistent, low-grade mucosal inflammatory processes, which might alter the interaction 
between the immune and neuroenteric system and leading via persistent visceral 
hypersensitivity to symptomatic IBS (9, 62). 
Travellers’ diarrhoea (TD) is a very common infection, among those visiting resource-limited 
destinations it is usually self-limited (1). Estimating 80 million travellers to high risk 
destinations and a mean TD incidence rate for a two-weeks stay of 30% (19 to 66%), some 24 
million would be affected per year (1). Previous studies among travellers found IBS incidence 
rates between 4 and 14% (5, 10, 63), but their conclusions were limited by the sample size of 
less than 500, the response rate and/or by their control for confounding factors. They were 
unable to generate data on age groups and travel destination. Therefore, we aimed to establish 
incidence rates of IBS among a cohort of mainly European travellers to various resource-
limited countries and to identify risk groups among those generally healthy travellers. The 




A prospective questionnaire-based cohort study with a follow-up six months post-travel was 
designed. To achieve a precision of +/- 2% at the level of a 4% pIBS incidence rate with a 
confidence of 1-alpha = 95% a sample size of n = 369 is needed. Due to an estimated TD 
incidence rate of 20 to 40 % and withdrawal rates of 30 to 50 % an oversampling by a factor 
of 4 to 10 (in the worst case) has to be applied. That resulted in at least 1600 study 
participants to be included.  
Participants. Adults seeking pre-travel medical health advice at the Centre of Travel Health 
of the University of Zurich between July, 2006 and January, 2008 were invited to voluntarily 
join the study. Upon having signed a written informed consent the following inclusion criteria 
were verified: German-speaking Swiss resident, duration of stay in a resource-limited 
destination with a high risk of TD (1) ranging from 1 to 8 weeks, also overall no longer than 
12 weeks within the six months following the index travel. Pregnant women, those who 
planned to use antibiotics for prophylaxis abroad, including doxycycline to prevent malaria, 
and those with severe chronic illness (anaemia, cancer, HIV, other diseases related to 
immunosuppression or immunosuppressive medication), previous gastrointestinal surgery, 
history of functional (FGID) or organic gastrointestinal disorders, recurring diarrhoeal 
symptoms, diarrhoea lasting over 14 days within the four months pre-travel period, and lastly 
those with undiagnosed IBS fulfilling Rome III criteria prior to travel were excluded. 
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Following recruitment all subjects received standard pre-travel health advice including 
information on basic preventive measures against diarrhoea.  
Definitions. IBS assessment was done according to the Rome III criteria (51); if associated to 
TD on the index trip it was defined as postinfectious IBS (pIBS) (64), while other IBS cases 
were labelled baseline IBS. Patients with IBS and those with similar symptoms were offered a 
free consultation at the Gastroenterology outpatient clinic of the Zurich University Hospital. 
The first consultation included a detailed medical history and physical examination. 
Depending on the discomfort, age and findings other examinations were performed afterward 
(blood and stool test, gastroscopy and colonoscopy with tissue biopsies, sonography, lactose 
breath test). TD and similarly pre-travel diarrhoea, were defined as three or more unformed 
stools per 24 hours with or without accompanying symptoms (18). A new TD episode had to 
be separated by a symptom-free interval of at least 72 hours. Continents and subcontinents 
were grouped according to the United Nations World Migrant Stock (22). Origin was the 
country in which the participant spent the first five years of life. ‘Newcomers’ were visiting 
the index travel region for the first time. The main categories of the International 
Classification of Diseases (ICD-10 2007) were used for co-medication and concomitant 
diseases. Allergies formed a separate disease entity including allergic asthma, allergic rhinitis, 
hymenoptera and atopic dermatitis, those were self-reported by the study participant, but an 
MD confirmation or corrected diagnosis was requested. Occurrence of major adverse life 
events (9) included death or major illness of a close family member or friend, loss of job or 
business failure, martial separation or divorce, major personal illness or injury experienced in 
the 12 months pre-travel.  
Study procedure. Three questionnaires were distributed: Pre-travel Q1, including thirty items, 
was collected at enrolment and aimed to determine travel characteristics (duration of stay, 
destination, purpose), medical and socio-demographic predictors (including gender, age, 
education, comorbidity and medication, level of stress (four-scale-rating), adverse life events, 
height and weight, allergies, origin, newcomer). Also data on pre-travel diarrhoea, 
susceptibility to TD, and family history of IBS were collected (1). Questions regarding 
alcohol consumption and smoking were categorized according to the Swiss Health Surveys of 
the Swiss Federal Statistical Office (65). Q2, either kept as a diary abroad or completed 
immediately after return, confirmed travel characteristics and investigated details on TD. 
Three months after the launch of the study additional questions on other syndromes abroad 
and on preventive practices to avoid TD were included to Q2. Q3 included 15 items and was 
sent per electronic or post mail six months after return from index travel at study endpoint. 
Therein IBS criteria, diarrhoea and other gastrointestinal symptoms within the past six 
months, any gastrointestinal drugs used and additional travel to resource-limited destinations 
were to be recorded.  
Non-responders were contacted twice by email and twice by post mail or telephone for Q2 
and Q3. Q2-non-responders were invited to at least report whether they had experienced 
diarrhoea abroad. Missing Q3s were evaluated with respect to their diarrhoea rates assessed in 
Q1 and Q2. No stool samples were evaluated. 
Statistics. Stata version 10.1 was used for descriptive, univariate and multivariate analyses. 
Differences between groups on categorical variables were tested by Fisher's exact test. 
Differences between groups on continuous variables were tested by the Wilcoxon ranksum 
test for independent samples with the alpha level of significance set at 0.05. The two weeks 
incidence rate and 95% confidence intervals (95%CI) were calculated based on Newcombe et 
al (26). A multivariate logistic regression model with IBS as outcome was used to establish 
relative risks (RR). At the beginning all variables were included, for later introduced variables 
(cf. study procedure Q2 section), we imputed the missing values based on gender, travel 
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continent and education. As sensitivity analyses, we evaluated independent risk factors for 
developing IBS with each half of the study participants, Further, we used another time 
schedule, assessing IBS 3 months instead of 6 months post travel. 
 
Role of the funding source 
The study was self-funded by the Division of Communicable Diseases at the Institute of 






A total of 3420 subjects were recruited and 2476 responded all questionnaires, thus the 
participation rate was 72.4%. Those who had to be excluded mostly reported pre-existing 
FGID and undiagnosed IBS (Q1) or they had changed their travel plans (Q2, Q3), (Fig. 1). 
Questionnaires (Q2 and Q3) were returned within a median 10 days after the first reminder. 
Among the study population gender was homogeneously distributed and a median age was 36 
years (range 18 – 82) (Table 1). The majority, 2320 (95.0%), originated from Europe, while 
65 (2.7%), including 11 visiting friends or relatives (VFR) were from a resource-limited 
country. The educational level was high, 1244 (51.3%) were university graduates. Popular 
tourist destinations were Southeast Asia, South Asia and East Africa, the median duration of 
stay was 3 weeks (range 1 – 12). For 181 (7.4 %) newcomers it was their first trip to a 
resource-limited destination. Business travellers were predominantly male (p = 0.0087), 
whereas age did not correlate with the type of travel. Among the 550 (22.2%) subjects 
reporting confirmed allergies, hay fever (378, 69.0%) and allergic asthma (92, 16.9%) were 
reported most frequently. A total of 852 (34.4%) subjects suffered from TD abroad, but only 
33 (3.9%) were among those 921 (62.7%) who rated themselves as being susceptible for 
diarrhoea. The TD incidence rate was not influenced by gender, but it occurred significantly 
more often in subjects under 25 years of age (p=0.0001). Males suffered significantly more 
often from pre-travel diarrhoea (p=0.021), while females reported more pre-travel adverse life 
events (p=0.008) and more susceptibility to diarrhoea (p=0.0224). 
 
Among the 313 non-responders of Q2 and Q3, but with available diarrhoea data,  18.4% 
(95%CI 14.8-21.1) had experienced TD and 14.5% (95%CI 11.6-17.3) pre-travel diarrhoea.  
 
IBS incidence rates and risk factors 
Thirty-eight (1.5% of the study population) developed IBS based on Q3 data, 26 (3.0% of the 
TD patients) being travel-related pIBS (table 2). Considering the baseline IBS incidence rate 
of 0.7%, the TD attributable risk difference is 2.3%. The overall IBS incidence rate for any 
two-weeks of stay was 1.0% (95%CI 0.6-1.4), and 2.8% (95%CI 1.7-3.9) for the subgroup of 
travel-related pIBS, respectively. In the multivariate logistic regression analysis TD was the 
strongest independent risk factor for developing IBS; also an adverse life event, and a pre-
travel diarrhoeal episode were relevant risk factors (table 3).  
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IBS patients more frequently reported multiple TD episodes abroad and a more severe TD 
course, e.g. dysenteric symptoms, than other diarrhoeal patients. For baseline IBS pre-travel 
diarrhoea was the only significant risk factor in the multivariate analysis (RR 3.80; 95%CI 
1.12-12.79). Any diarrhoeal episode increased the risk of developing IBS more than fivefold 
(pre-travel diarrhoea or TD: RR 5.60; 95%CI 2.55-12.29) with insignificant differences when 
comparing pre-travel diarrhoea and TD. Experiencing multiple diarrhoeal attacks raised the 
IBS risk by sixfold (RR 6.01; 95%CI 2.02-17.89) when controlled for gender, age and an 
adverse life event. For all the above analyses a concordant about threefold increased risk for 
having experienced an adverse life event within the past 12 months was detected. 
 
For the sensitivity analysis the multivariate logistic regression results of the total study 
population were compared to the ones of each half and the same independent risk factors were 
found. For a follow-up period limited to 3 months post-travel a lower overall 3-months-IBS 
incidence rate (0.9%; 95%CI 0.5-1.3; n=22) was detected and the corresponding overall 
travel-duration-related IBS incidence for any two-weeks of stay was 0.6% (95%CI 0.3 -0.9). 
 
IBS classification and healthcare utilization 
The majority of IBS patients were classified as mixed IBS-M (31, 81.6%), four patients 
(10.5%) had diarrhoea-predominant IBS-D, three (7.9%) constipation-predominant IBS-C. 
Seventeen (44%) patients sought medical care, ten among them spontaneously consulted a 
physician and the remaining seven were supposed to visit the Gastroenterology outpatient 
clinic at the University Hospital. Three of them were diagnosed with IBS, one patient was 
diagnosed with lactose intolerance, blastocystis hominis was found in one patient, one had a 
prolonged travellers diarrhea and the seventh patient finally did not show up. Among those 
consulting a physician spontaneously we received one IBS-confirmation by a 
gastroenterologist and a self-reported case by a patient who visited several physicians. The 




This is the first large prospective cohort study to focus on irritable bowel syndrome among 
travellers to resource-limited destinations on various continents using the Rome III criteria. 
New onset of IBS assessed 6 months post travel has occurred overall in 1.5%, and 3.0% had 
TD-related pIBS. Our IBS incidence rates are in the same range as the ones found for the 
general population of 1 to 3% per year, but below the pIBS rates of 3.7 to 36% (7, 61) or of 
the 4-14% reported for TD-related pIBS (5, 10, 63). The TD attributable risk difference of 
2.3% is similar to the one of the initial Ilnickyj study reporting a risk difference of 2.6% (63), 
but we assessed baseline and pIBS with a far larger sample size. Our lower IBS rates in 
travellers may be explained by the efforts in separating diarrhoeal episodes and by the more 
stringent exclusion criteria; having for instance detected 189 cases of pre-existing (un-
)diagnosed organic or FGID at recruitment. In addition, the destinations and the study 
populations differed, e.g. we included also senior citizens as compared to some of the 
previous studies (19). The follow-up in all previous travelers-based studies was 3 or 6 
months, but diagnostic criteria used were Rome I (3 months follow-up) and Rome II (12 
months). After 3 months our overall IBS-3-months incidence rate resulted the half (0.9%). 
Compared to the results of a meta analysis it remains uncertain whether a longer follow-up of 
our patients would have resulted in higher incidence rates of IBS (7). 
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Three kinds of selection bias might limit our study: Travellers consulting for pre-travel health 
advice might be either somewhat hypochondriac or represent a particularly health literate 
subpopulation with a positive health awareness, as 51.3% of our customers reported a 
university degree. The latter would result in an underestimation of the IBS risk when 
compared to travellers with a different educational background whereas for the former higher 
TD rates and also a higher rate of IBS would be expected. Actually, we found higher TD rates 
when compared to non-responders and this might indicate even an overestimation of our IBS 
incidence rate. Third, some popular tourist destinations, such as Turkey, North Africa and the 
Caribbean, although attracting millions of visitors, are underrepresented as those rarely 
consult for pre-travel health advice (66).  
 
Diarrhoea is an important risk factor for IBS whether it occurred at home or abroad. There is 
evidence that new onset of IBS may be triggered by an infectious agent, but it remains 
unknown, whether the type of pathogen, the size of the inoculum, and the time interval 
between diarrhoeal attacks play a role (67). Of note, it appears that multiple diarrhoeal 
episodes would raise the IBS risk. That might support the hypothesis of IBS being a persistent 
or re-activated mucosal low-grade inflammation (62). As the results of the sensitivity analyses 
validate our risk estimates, more detailed subgroup analyses were not feasible, but such would 
be needed to assess factors and syndromes associated with other low-grade inflammatory 
processes, as e.g. bronchial hyper-responsiveness (68) or antibiotic treatment (9) were shown 
to be associated with IBS.  
The reported threefold IBS risk following the experience of a recent adverse life event 
corresponds to the relative risk of 2.0 for IBS found by Gwee et al. (69) who evaluated the 
risk levels of psychological factors and gut dysfunction among IBS patients. In our cohort 
only one IBS case reported regular antidepressive medication. Contrary to some reports, 
female gender was not found to be a significant independent risk factor for IBS, potentially 
masked by underlying factors, such as mental health issues or TD characteristics.  
 
Of practical importance for travel medicine, we estimated a TD-associated IBS risk of 2% in 
the 6 months following any two-weeks stay at a resource-limited destination. Still substantial 
and almost twice the incidence rate of self-limited influenza in a comparable population, IBS 
has a greater impact because it represents a long-term travel sequelae in a previously healthy 
population. 
 
Research is needed to determine whether extensive preventive measures, e.g. by antibiotic 
prophylaxis, would reduce the risk of IBS in travellers as has been postulated (70). If this is 
confirmed, travel health counsellors in the pre-travel consultation could investigate 
predisposing factors, such as recent diarrhoeal episodes, the experience of recent adverse life 
events and discuss the means to reduce the risk for IBS. Further investigations also need to 
focus on the patho-physiological interaction of IBS predisposing factors. 
 
Partly presented in part at the 11th Conference of the International Society of Travel 
Medicine, Budapest, 24–28 May 2009 (abstract FC 03.01).
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Table 1: Selected sociodemographic, travel and health-related data of all travellers and those 









Female gender 1258 (50.8) 18 (47.4) 0.669 
Age, median (range) in years n = 2370  
36 (18-82) 




Continent visited:  Africa 
   Asia 










Duration of trip, median (range) in weeks 3 (1-12) 3 (1-8) 0.192 
Purpose of travel  
   tourism 
   visiting friends and relatives 













Newcomer (first visit to resource-limited countries) 181 (7.4) 6 (15.8) 0.046 
Travellers’ diarrhoea (TD) 852 (34.4) 26 (68.4) 0.000 
 ! 2 TD episodes 226 (9.2) 12 (31.6) 0.011 
 severe TD symptoms:  dysentery 







 TD duration, median (range) in days 2 (1-90) 3 (1-20) 0.312 
Allergies, self reported as MD diagnosis 550 (22.2) 11 (28.9) 0.840 
 Hay fever 378 (15.3) 9 (23.7) 0.357 
 Allergic asthma 92 (3.7) 4 (10.5) 0.027 
Diarrhoea " 4 months pre-travel, resolved pre-departure 305 (12.3) 12 (31.6) 0.000 
Duration of diarrhoea pre-travel, median (range) in days 2 (1-10) 2 (1-5) 0.988 
Adverse Life Event  " 12 months pre-travel n = 2452 
230 (9.4) 




















Close family member with IBS n = 1331 
58 (7.5) 





 Chi square / Wilcoxon rank sum test 
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Table 2: Incidence rates for irritable bowel syndrome (N = 2476)  
 6-months incidence rate 95%CI 
IBS overall 1.5 (38/2476) 1.1 – 2.0 
Postinfectious IBS 3.0 (26/852) 1.9 – 4.2 
Baseline IBS 0.7 (12/1624) 0.3 – 1.2 
   
 
Travel duration-related 6-months 
incidence for any two-weeks of stay 
95%CI 
IBS overall 1.0 0.6 – 1.4 
Postinfectious IBS 2.8 1.7 – 3.9 
Baseline IBS 0.9 0.5 – 1.4 
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Table 3: Relative risk estimation of developing IBS 6 months post-travel. 
Variable Univariate  
Risk ratio (95% CI) 
N = 2476 
Multivariate regression  
Risk ratio (95% CI) 
N = 2424 
Multivariate regression 
Risk ratio (95% CI) 
Base Model, N=2424 
Female gender 0.87 (0.46-1.65) 0.89 (0.46-1.71) 0.89 (0.46-1.71) 
Age " 30 years 
1)
 2.48 (1.27-4.84) 0.89 (0.76-1.04) 0.89 (0.76-1.04) 
Newcomer 
2)
 2.39 (0.99-5.80) 2.43 (0.98-6.02) 2.43 (0.98-1.71) 
Travel duration ! 2 weeks 1.18 (0.98-1.41) 1.09 (0.91-1.31)  
Travel destination 
 Africa vs. Asia 
 Asia vs. Latin America 












Visiting Friends and Relatives 
  vs. tourism 










Smoking  1.71 (0.90-3.29) 1.66 (0.85-3.20)  
Allergic asthma 3.18 (1.08-9.41) 2.32 (0.75-7.16)  
Adverse Life Event 
3)
 3.08 (1.44-6.59) 3.11 (1.40-6.78) 3.11 (1.43-6.78) 
High stress-level pre-travel 1.00 (0.30-3.28) 0.73 (0.21-2.51)  
Diarrhoea pre-travel 
4)
 3.38 (1.69-6.77) 2.74 (1.34-5.61) 2.74 (1.34 – 5.61) 
Travellers’ diarrhoea (TD) 4.23 (2.12-8.42) 3.67 (1.82-7.40) 3.67 (1.82-7.61) 
 ! 2 TD episodes 2.88 (1.22-6.76) 2.71 (1.14-6.47)  
 dysentery 4.44 (2.00-9.88) 3.48 (1.53-7.93)  
 Duration of TD  1.02 (0.98-1.06) 1.02 (0.97-1.06)  
Antibiotic intake on travel
5)
 2.65 (1.09-6.45) 2.27 (0.92-5.60)  
Malaria chemoprophylaxis 0.91 (0.40-2.09) 0.88 (0.38-2.03)  
TD-risk practices abroad 
6)
 1.53 (0.34-6.94) 1.79 (0.39-8.29)  
Multivariate analysis controlled for gender, TD, diarrhoea pre-travel, adverse life event and newcomer (Base 
Model) 
1)
 Age substituted by newcomer in multivariate analysis, as newcomer is dependent from age (p= 0.000) 
2)
 First visit to resource-limited countries 
3)
 Experienced within 12 months pre-travel 
4)
 Episode within 4 months pre-travel and resolved pre-travel 
5)
 Subjects taking antibiotic prophylaxis excluded
6)
 Self-reported non-adherence to the adage “cook it, boil it, 
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CHAPTER III 
 
Evaluation of selected health problems abroad: prospective and 
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ABSTRACT 
 
Background. Within the past decades many studies investigated travellers’ health either 
prospectively or retrospectively. Aim is to evaluate strengths, limitations and common issues 
of prospective and retrospective traveller-based datasets with respect to selected common 
health impairments among Swiss travellers to resource-limited destinations. 
 
Method. Two prospective questionnaire-based cohorts A (2006-08) and B (1998-2000) 
included adults with standard pre-travel medical advice travelling ! 8 weeks to resource-
limited destinations. They were compared to a retrospective, post-travel and physician–based 
collective of Swiss patients with or without pre-travel health advice, the Swiss GeoSentinel 
database (2004-2005). 
 
Results. In both cohorts travellers suffering from health problems abroad tended to be 
younger (RR age A(18-25 years) 1.53; 95%CI 1.12-2.08 and B (12-25 years) 1.12; 95%CI 
0.85-1.47), stayed longer abroad (RR weeks of stay A 1.27; 95%CI 1.20-1.36 and B 1.08 
95%CI 1.05-1.11) and had more frequently visited the Indian subcontinent (RR A 1.79; 
95%CI 1.38-2.36 and B 2.07; 95%CI 1.36-3.16). Travellers of median age 36 and 31 reported 
any illness abroad in 43% and 40% of all 2476 (cohort A) and 1435 participants (cohort B), 
respectively. Diarrhoeal, attack rates (A. 34% and B: 26%) accounted for the most frequent 
contracted infectious impairment abroad, followed by cold (A 10%; B17%) and 5%A; 10%B 
participants measured fever. Physician visits for any reported illness abroad accounted for 8% 
for both cohorts. Females were significantly more frequently affected by constipation and 
insect biting, males by fever. 
 
Conclusions. Prospectively collected questionnaire results and retrospectively assessed MD 
diagnosis-based data complement each other. Whereas the first provides an overview of 
health impairments occurring among travellers and estimates absolute risks, as e.g. 
incidences, the latter focus on more serious or persistent health problems needing health care 
utilization. 
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BACKGROUND 
Among the various studies assessing health risks of travellers to resource-limited destinations 
two different main approaches might be distinguished: first, a crosssectional, usually patient-
based design, such as the GeoSentinel database which collects travel characteristics 
retrospectively (71). Second, a prospective cohort design assessing travel- and health-related 
information pre-travel and including a diary to record health impairment while abroad or 
shortly after return (72). We aimed to contrast these two approaches to point out their 
strengths, limitations and common issues. Thereby, we based on known frequent health 
problems abroad, such as travellers’ diarrhoea (TD) which affects 20-60% of individuals from 
industrialized countries visiting a resource-limited destination(1, 73), Pitzurra R et. al. BMC 
Infect Dis submitted), respiratory tract infections being with 26%(74) the second most 
common cause of illness in returned travellers including fever, which is as frequent as 
13%(75),  skin rashes abroad accounting for 8%(76) and the often neglected constipation with 




Setting and participants 
 The two prospective travellers-based cohorts, A and B (BMC Infect Dis submitted and Isefit 
(72) were done in Zurich at the Travel Health Centre of the University of Zurich, and the 
patient-based GeoSentinel networks’ dataset included data of Switzerland(78) to get a 
comparable study population with respect to place of residence. Cohort A was performed 
from July 2006 to January 2008, cohort B between January 1998 to March 2000 and Swiss 
included data from 2004 to 2005. Participants of cohorts A and B had all provided written 
informed consent and had received standard pre-travel medical advice and the standard as 
well as the recommended immunisations against vaccine-preventable diseases. Within 
GeoSentinel data information about medical pre-travel consultation and updated vaccination 
status was available. For reasons of comparability and of frequent occurrence diarrhoea, fever, 
cold symptoms and skin rashes were selected as model illness entities. 
Table 1 reports an overview of case series and cohort design. 
Data analysis 
For the cohort studies, statistical significance of variables was assessed ranksum-Wilcoxon 
nonparametric tests and relative risks with 95% confidence intervals with a level of 
significance set at 0.05. Multivariate analysis with logistic regression was performed with 
adjustment for gender, age, destination, travel duration, purpose of travel and the diseases 
(travellers’ diarrhoea, cold, fever, constipation and skin rashes) using either any disease, TD 
or cold as separate outcomes. Data were analyzed with the software Stata Statistics 10.1. The 
Swiss GeoSentinel data were based on published data and personal communication of the 
Swiss coordinator. 
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Gender and age were similarly distributed among all three datasets (Table 1). Among 
resource-limited destinations places in Asia were most frequently visited followed by Africa 
and Latin America.The median travel duration was with 3 weeks slightly longer than for the 
GeoSentinal data with a median of 14 days. The great majority (> 80%) traveled as tourists 
followed by less than 10% of business travellers and VFRs (those visiting friends and 
relatives) whereas the VFRs accounted for more than one third in the GeoSentinel study. 
 
Ranking of illness 
Cohorts A and B did not different significantly within the symptom spectrum reported. More 
than half of all cohort study participants reported any health impairment (Table 2). Within the 
cohort studies gastrointestinal illness was most frequently mentioned followed by respiratory 
symptoms, common cold, fever and skin rash whereas within the Swiss GeoSentinel data 
gastrointestinal diseases and fever ranked at the top followed by respiratory illness and skin 
disorders. Of note, a total of 1045 (72.8%) reported insect bites, of which 50 (80.7%) in 
combination with skin rashes, but no significant association was found neither with skin 
rashes (p= 0.1245) nor fever (p=0.7714).  
 
Risk factors 
Figure 1 shows shows the relative risks for developing any self-reported illness abroad, 
including the significant RR for visiting the Indian subcontinent, longer travel durations, age 
below 25 in both cohorts and VFR only for cohort A.  
Focusing on gender differences (for females) we found constipation to be the most prominent 
risk factor (RR Cohort A 2.53; 95% CI 1.14-4.53; RR Cohort B 1.71; 95% CI 1.03-2.81). The 
cohort A women appeared to be less at risk of experiencing fever (RR 0.74; 95% CI 0.54-
1.00). Especially in relation with TD, RR for dysentery was 0.68 (95% CI 0.48-0.95). 
Remarkably, significantly more women reported adhering to the adage “cook it, boil it, peel it 
or forget it” (pCohort A=0.0274). More men reported tap water consumption (52.7%; pCohortA = 
0.224). In both cohort studies measured fever temperature was similarly distributed (median 
38.5; rangeCotravibs 37.5-41.5, rangeIsefit 37.5-40.7). ) Interestingly, females were more 
vulnerable for insect bites (p=0.0144). 
No other divergent gender characteristics were observed, except that more males went for 
business trips in both studies (pcohort A=0.0092, pIcohort B=0.0116). 
For outcome TD we found in multivariate analysis significant common risk ratios for 
increasing age (RR A 0.99; 95%CI 0.98-1.00 and B 0.99; 95%CI 0.94-1.00), the Indian 
subcontinent (RR A 2.55; 95%CI 1.84-33.54 and B 1.54; 95%CI 0.84-2.81), duration of stay 
(RR A 1.30; 95%CI 1.21-1.39 and B 1.03; 95%CI 1.00-1.07), and constipation (RR A 0.01; 
95%CI 0.01-0.05 and B 0.16; 95%CI 0.05-0.48). For cold as outcome we found in the 
multivariate analysis the following independent risk factors: travel duration (RR A 1.12; 
95%CI 0.99-1.27 and B 1.00; 95%CI 0.97-1.04), and fever (RR A 6.13; 95%CI 4.38-8.59 and 
B 2.34; 95%CI 1.46-3.72). 
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Physician visits  
One third (32.8%) of all cohort A participants either healthy or impaired, reported a MD visit 
abroad, among cohort B subjects there were one of seven (13.8%), but only TD data was 
available. When only proportions of those reporting any illness were considered very similar 
rates for cohort A (13.8%) and cohort B (13.7%) were obtained (hospitalisation excluded). At 
home 128 (20.8% of any illness) of cohort A and 46 (5.4% of TD cases) of cohort B patients 
reported doctors’ consultation. 41 (4.6%) of cohort B and 14 (1.1%) of cohort A had visited 
MDs both, at home and abroad. 
Incapacitation defined as staying at the hotel room for a minimum of 12 hours or consulting a 
physician abroad accounted in cohort B to 323 (36.0% of ill ones) confined for a median of 2 
days to bed (range 1-14) and 95 (11.2% of TD cases) for cohort A. 
For cohort A information regarding IBS and physician visits 6 months post-travel were 
available 55 (2.2%) visited a MD for any bowel problem and so did 10 of 38 (26.3%) subjects 
with travel-related Rome III – IBS. 
Independent risk factors for visiting a physician included travel duration (RR A 1.26; 95%CI 
1.11-1.41 and B 1.08; 95%CI 1.05-1.11), Indian Subcontinent (RR A 1.90; 95%CI 1.14-3.16 
and B 1.87; 95%CI 1.13-3.10) and fever (RR A 9.91; 95%CI 6.13-16.12 and B 6.44; 95%CI 
4.33-9.57) among subjects of both cohorts each in a logistic multivariate regression subgroup 




According to our cohort studies, travellers who mentioned health problems abroad tended to 
be at the age extremes, young adults and the elderly, stayed longer abroad (maximum of 8 
weeks) and had visited more frequently the Indian subcontinent. In addition, the Swiss 
GeoSentinel data(78) have shown the increased health risk of VFRs abroad with 80% missing 
pre-travel medical advice. Within cohort A we have found concordant results although VFRs 
were underrepresented in our travel clinic. 
Certain popular tourist destinations, such as Turkey, North Africa and the Caribbean generally 
observe high travel volumes and TD rates (1, 15) but these visitors are underrepresented in 
asking for pre-travel medical advice (31), e.g. only 52.1% of responders departing to 
resource-limited destinations had sought travel health advice at European airports (66). 
Diarrhoea was rated in both settings at the top of travel-related syndromes threat(1, 19) with a 
predominance on the Indian Subcontinent, as was also found in the GeoSentinel network 
when assessing gastrointestinal infections globally(79, 80) and in other studies (1, 81). 
Respiratory tract infections are also commonly associated with travel, whereby nonspecific 
upper respiratory tract infections were most frequently diagnosed with 47.2% including 
20.3% of bronchitis(74). The evidence showed that cold symptoms were often linked with 
fever and influenza infection is known to occur with a two-weeks incidence of 1% among 
travellers to resource-limited destinations(72). Of note, fever was associated with male gender 
(RR A 1.36; 1.00-1.84), which is in agreement with the Swiss GeoSentinel data (CID in 
press) estimating an odds for febrile systemic illness  for females of 0.64; 95% CI 0.61-0.67).  
Actually, constipation is a rather neglected topic in the travel medicine literature and in pre-
travel health consultation. So far, Spanish scientists detected among travellers to Argentina a 
higher attack rate of  constipation of 38% than of diarrhoea (8%)(77). Among our cohorts 
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lower attack rates were found, 2.3% and 13%, respectively, predominantly among females, 
but we only collected self reports and defecation frequency for assessing functional 
constipation(17) was not determined. Changes in diet, time zone, lack of activity while flying 
or on bus trips, and known side-effects of motility blocking medication are all putative 
contributing factors. Chang et al. (82) observed among US residents a  significant association 
with analgesics (e.g. seven or more tablets of acetaminophen) excluding IBS symptomatics.   
Overall, females were more at risk for constipation and insect bites but they showed better 
compliance with food hygiene attitudes as well as a lower risk for getting fever or suffering 
from dysentery. 
 The two cohort studies were primarily designed to establish in the case of cohort A TD 
and postinfectious IBS, and in the case of cohort B fever-associated infections. Hence, TD 
reports in cohort A and fever in cohort B might slightly be overestimated as demonstrates the 
comparison of these two studies.  
The pre-travel advised traveller is known to be health literate (often high educated), 
vaccinated, maybe hypochondriac, uses more self-medication and needs less physician visits. 
About 10% of the patients visited a physician abroad and roughly an additional 10% at home, 
mostly when fever occurred, with longer travel duration or when visiting the Indian 
subcontinent. 
The case series of the GeoSentinel data and the cohort studies share common features, such as 
to identify (re-)emerging or neglected health problems and to determine travel-related risk 
factors and populations at special risk, as e.g. age groups, gender, longer stay, travel to the 
Indian subcontinent. On the other hand, case series usually target more serious health 
problems or those travellers are unable to cope with alone and ask for a MD diagnosis, often 
not at a primary care practice(83). Cohort studies, however, are able to provide an overview 
of the variety of health problems travellers potentially face abroad but for a detailed 
assessment they usually concentrate on selected health problems for reasons of feasibility. 
Due to available denominator data the magnitude of a risk can be estimated, e.g. as incidence 
rate. Therefore, both approaches represent puzzle pieces needed to obtain a complete picture 
of travel-related health impairments. 
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Table 1. Comparison of case series and cohort design 
Factor Cohort studies Case series 
Data collection Prospective Retrospective 
Population Travellers with pre-travel health 
advice 
Ill returned travellers 
Setting Approximation to travel groups 
& destinations 
Health care 
Exposure assessment Pre- and post-travel Post-travel 
Time frame Usually limited to months or 
some years 
Potentially long-term 
Budget high Usually in addition to health 
insurance 
Aim Overview, risk estimates and 
risk factors, evaluation of pre-
travel health advice, KAPs or 
health care utilization 
Surveillance, risk factors, 
evaluation of pre-travel health 
advice 
Risk estimates Relative and absolute, risk 
ratios, incidence 
Relative, odds ratio 




Spectrum of health problem All types, usually limited Usually more severe 
Accuracy of health assessment Case definition based Guidelines-based, maybe 
differences by Centres 
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Table 2. Demographic and Travel characteristics 
 Cohort A 
Cotravibs  
 










N = 338 
year of study course 2006 – 2008 1998 – 2000  2004 – 2005 
Gender percentage of female/ 







Age, median (interquartile range) 36 (29-47) 31 (26-43)  32 (32-46)  
Travel destinations     
  Africa 
b)
 808 (32.7) 447 (30.8) 0.5247 70 (20.7) 
  Asia including India 1105 (44.7) 566 (39.0) 0.1925 82 (24.3) 
  Indian subcontinent 422 (38.2) 130 (23.0) 0.7600  
  Latin America 557 (22.6) 393 (27.1) 0.7774 31 (9.2) 
  Other - 44 (3.0)  155 (45.9)
 c)
  
Duration of stay, median (interq. range) 3 weeks (2-4) 3 weeks (2-5)  15 days (11-24) 










  102 (7.0) 











 Wilcoxon ranksum test for Cotravibs vs. Isefit 
b)
 Geosentinel Data contains only subsaharan 
c)
 Geosentinel Data contains also Eastern Europe 
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Table 3. Reported Illness during Travel. 
 Cotravibs 
Cohort A 
N = 2476 
Isefit 
Cohort B 
N = 1435 
p Hill D.R. 
et al.(75) 
 




N = 670 
any 1081 (43.6) 578 (40.3) 0.0462 501 (63.9)  
gastrointestinal     117 (53.9) 
 diarrhoea 852 (34.4) 375 (25.9) 0.1003 270 (34.4) 79 (18.4) 
 dysentery 146 (5.9) 164 (11.3) 0.6799 64 (8.2)  
 constipation 57 (2.3) 68 (13.0) 0.6040   
respiratory      
cold 254 (10.2) 244 (16.8) 0.1834 204 (26.0) 86 (12.8) 
systemic      
measured fever 131 (5.3) 147 (10.1) 0.5593 100 (12.8) 165 (24.6) 
dermatological      
skin rash 17 (0.7) 64 (4.4) 0.7112 63 (8.0) 44 (6.6) 
other 235 (9.5)
a)
   218 (27.8) 210 (31.3)
c)
 
Multiple 239 (9.7) 229 (15.8) 0.3931   
      
physician visit 
 abroad 
 at home 
 hospitalisation  
 abroad 
only for TD: 
65 (7.6) 
53 (6.2) 
  4 (0.2) 

















 94 with headache, 57 with altitude sickness, 44 with arthalgia, 40 other 
b)
 gastrointestinal 165 (24.6) 
c)
 92 with head/ear/nose, 47 Musculoskeletal, 37 Fatigue, 34 Other 
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Figure 1. Legend: Independent relative risk factors for self-reported illness estimated with a 
multivariate logistic regression analysis 
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GENERAL DISCUSSION AND OUTLOOK 
 
Our particular traveller-based data report remarkable rates of travellers’ diarrhoea (TD any 2-
weeks incidence 27%) and a – lower than expected – IBS incidence of 1% within 6 months 
post-travel. The incidence of IBS in the general population is reported to be 1-3% (84). Our 
postinfectious IBS incidence rate 6 months post-travel was found to be 3%. Previous 
traveller-based studies (5, 10, 85) showed, that 4 - 10% of TD patients would develop IBS. 
Table 1 compares this study with the previous four ones among travellers. They all use the 
same prospective cohort design with TD as exposure factor but they differ in methods used as 
i.e. sample size, accurate definition of exclusion criteria and control for potential bias. We 
excluded any (un-) diagnosed organic and functional gastrointestinal disorder as well as 
persistent diarrhoea pre-travel. It seems possible that subjects with those pre-morbid 
gastrointestinal symptoms switched to new IBS cases in these previous studies. Table 2 
compares this study with other pIBS studies among community settings. Also the community 
settings reported higher pIBS incidence rates. Hereby could the characteristics and load of the 
infectious agent play a role, we had mixed pathogen spectrum with TD, others outbreaks with 
a single pathogen e.g. Campylobacter infection transmitted via regional water supply.  
Diarrhoea – whether it might be acquired at home or abroad is the most important risk factor 
for IBS, furthermore multiple diarrhoeal episodes raise the risk of developing IBS. These 
findings support the hypothesis that IBS might be a syndrome resulting from a persistent or 
re-activated low-grade inflammation. Inflammation is associated with production of mediators 
including prostaglandins, nerve growth factors and 5-hydroxytryptamine. These mediators 
induce visceral hypersensitivity, exaggerated motor responses, and increased intestinal 
secretion, which may contribute to episodic diarrhoea (55). 
 
IBS in general might confuse physicians and researches by its multifaceted phenomenon, 
changing symptoms over time and absence of biological markers. Its diagnostic criteria have 
been frequently redefined and the present study just started when Rome II switched to Rome 
III. Rome II required a longer study period of 12 months, which could also be an explanation 
for our lower incidence rates. Longer study periods partially resulted in increasing incidences 
(59, 86, 87).  
Ideally, more IBS positive cases should have occurred during our study period for deeper 
analysis. Larger number of individuals could be reached in future by including hospital or 
health Centre pools, although these patients represent different settings and may used more 
for case-control studies.  
 In chapter III we compared prospective cohort study design with the retrospective case 
series approach. The former represent the best strategy to determine the incidence and natural 
history of a disorder (in our case TD and IBS), when exposure factors and measurable 
outcome are clearly defined at the beginning. Figure 2 represents how cohort studies track 
participants forward in time from exposure to outcome. In figure 3 this scheme was applied to 
our case. 
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Our results are a clinically relevant piece of information to medical decision makers and the 
travellers’ community. Every pre-travel consultation has to discuss TD and its management, 
with special dedication to the risk groups like e.g. diarrhoea susceptible subjects. Reviewing 
so with visitors of (sub-)tropical destinations the basic TD preventing behaviour, bearing well 
in mind, that the feasibility in exotic surroundings is restricted (24, 25). Medical experts and 
travellers should demand for safe food and water supply as well as hygienic infrastructure for 
lavatories to decrease the diarrhoea burden (49). Discussion of TD management (antibiotic 
and non-antibiotic) with written instructions for emergency treatment is very useful. 
Furthermore promising TD vaccines and prophylactic medication are on the way to prevent 
TD and consequently, postinfectious IBS (88, 89).
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 Pitzurra et al. Stermer et al. Okhuysen et al. Illnyckyj et al. 
Methods     
study design prospective cohort of 
travellers 
prospective cohort of 
travellers 




year of study 2006-2008 2004 2002 1997-1998 
Assessment questionnaires questionnaires questionnaires questionnaires 
control group Yes (unexposed) Yes (unexposed) Yes (unexposed) Yes (unexposed) 
exposure TD, self-reported TD, self-reported TD, self-reported TD,self-reported 
follow-up 
(months) 
6  6 6 3 
diagnosis 
criteria 


























• GI history 




• previous organic 
bowel disease 
• or functional 
bowel disease 
• chronic GI 
symptoms 
• Meeting Rome I 
or Talley criteria 
pre-travel  




of the Travel Health 
Centre Zurich 
Travel Clinic Bnai Zion 
Medical Centre Haifa 
(Israel) 
N American students 
Houston (Texas, 
USA) 
Central civic or 
private travel clinic & 
by advertisements 
(Canada) 
Sample size 3420 564 176 198 
response rate (n 
analysed) 
72% (2476) 72% (405) 57% (97) 55% (109) 
Results     




Baseline IBS % 
(n) 
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TD cases 
(attack rate) 












Female gender 50.8% 46.7% 50.5% 55.5% 
Age, mean 
(range) 





Destinations resource-limited & 
high TD risk 
  45% Asia 
  33% Africa 
  22% Latin America 
 
 84% Asia 





outside US or 
Canada 
  15% Mexico 
  7% India 
  6% Cuba 
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Figure 3. Our prospective cohort study design with questionnaires (Q), Travellers’ 
Diarrhoea (TD) as exposure factor and Irritable Bowel Syndrome (IBS) as outco
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Wissenschaft l iche Studie zu Reisedurchfal l  und dessen Folgen 
 
Reisedurchfall tritt in Entwicklungsländern häufig auf. Wenig bekannt ist, dass dieses lästige Übel 
gelegentlich zu chronischen Darmstörungen führen kann, welche über Monate oder Jahre anhalten. Um 
festzustellen, wo und wie häufig mit derartigen langwierigen Problemen zu rechnen ist, laden wir Sie ein, 
an einer Studie teilzunehmen.  






Wenn Sie beitragen wollen, Reisende künftig noch besser informieren und beraten zu können, so 
beantworten Sie doch bitte hier in der Wartezeit nachfolgende Fragen.  
Auf die Reise erhalten Sie einen kurzen Fragebogen und einen weiteren kurz nach Ihrer Heimkehr. Letztes 
Frageformular bitten wir Sie 6 Monate später auszufüllen. Teilen Sie uns bitte mit, wenn sich Ihre Adresse 
ändern sollte. 
Sollten sie nach 6 Monaten tatsächlich noch an Darmstörungen leiden, so bieten wir Ihnen unentgeltlich 
eine Beratung durch Darmspezialisten im Universitätsspital Zürich an — gemeinsam werden Sie 
bestimmen, ob weitere Abklärungen angebracht sind. Daraus allenfalls resultierende Kosten sind 
krankenkassenpflichtig. 
Gesundheitsrisiken erwachsen Ihnen aus dieser Studie nicht, da im Verlauf der Stud ie  
weder Laboruntersuchungen statt f inden noch Sie irgende in Medikament e rha lten — wi r  
bit ten Sie ledig l ich, etwas Zeit  zu invest ie ren.   
Teilen Sie uns bitte mit, falls Sie je Komplikationen oder Operationen im Magen-Darm-Trakt hatten. 
Selbstverständlich werden alle Daten anonym ausgewertet und jederzeit können Sie ohne Angaben von 
Gründen auf die weitere Teilnahme an der Studie verzichten. Sie können uns auch angeben, ob Sie 
wünschen, dass wir Ihnen einen Kurzbericht zustellen.  
 
Ihre Teilnahme und Ihre Zufriedenheit ist uns wichtig! Haben Sie Fragen noch bezüglich Durchfall und 
neuesten Stand seiner Medikation? 
Unter denjenigen, welche uns auch den letzten Fragebogen Q3 (nach 6 Monaten) zurücksenden,  
verlosen wir Reisegutscheine (1 x 1000 CHF, 4 x 500 CHF)sowie Gutscheine für eine reise-
medizinische Beratung (15 x 200 CHF). 
Zudem können Sie sich vor Ihrer nächsten Reise telefonisch einen Termin für eine reisemedizinische 
Beratung reservieren (während der offiziellen Beratungszeiten) und werden dann ohne Wartezeit beraten!
Universität Zürich 
Zentrum für Reisemedizin 
pitzurra@ifspm.uzh.ch     Tel. +41(0)44 634 46 46 
 
World Health Organization 











Ich willige ein, an der Studie "Reisedurchfall und deren Folgen" teilzunehmen — allfällige Fragen konnte 
ich mit dem Team des Zentrums für Reisemedizin der Universität Zürich besprechen. 
 
 
Name/Vorname (Druckschrift) :  ___________________________________ 
 
 email (reminder, kein Spam) :  ____________________________________ 
  
 ! (wichtige Nachfragen) :   _______________ 
 
 






Datum      Unterschrift                                            
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Eintrittsfragebogen Q1 
 Datum:   ID – Nr.   
 
1. Litten Sie je über mehrere Monate an Unwohlsein oder Schmerzen im Bauch  (an 
 mindestens zwei Tagen pro Woche)? (Menstruationsbeschwerden ausgenommen) 
 !  NEIN !  weiter zu  Frage 8. ! JA "  weiter zu Frage 2. 
2. Besserten sich das Unwohlsein oder die Schmerzen nach dem Stuhlgang oder hörten 
 sie ganz auf? 
   !  NEIN  ! JA 
3. Als das Unwohlsein oder die Schmerzen begonnen haben, hat sich die Häufigkeit Ihres 
 Stuhlganges verändert (entweder häufiger oder seltener Stuhlgang)? 
   !  NEIN  ! JA 
4. Als das Unwohlsein oder die Schmerzen begonnen haben, hatten Sie anderen (eher 
 weicheren oder härteren) Stuhl festgestellt als üblicherweise? 
   !  NEIN  ! JA 
5. Traten in den vergangenen 6 Monaten während mindestens 6 Wochen (mindestens  an 
 einem Tag pro Woche) eines der folgenden Symptome auf?  
 Bitte alles Zutreffende ankreuzen. 
   !  Stuhlgang weniger als dreimal pro Woche 
   !  Stuhlgang häufiger als dreimal pro TAG (4 mal oder mehr) 
   !  harter oder klumpiger Stuhl 
   !  wässriger, ungeformter oder breiartiger Stuhl 
   !  Krämpfe während des Stuhlganges 
   !  Gefühl einer unvollständigen Entleerung nach dem Stuhlgang 
   !  Völlegefühl, Blähung oder Anschwellen im Unterbauch 
   !  Ein Gefühl, dass der Stuhl während des Stuhlganges blockiert ist 
   !  Ein Bedürfnis, mit Druck eine vollständige Stuhlentleerung erreichen zu müssen 
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6. Wurde ein „nervöser Darm“, bzw. ein „Reizdarm-Syndrom“ je durch einen Arzt 
 bestätigt? 
  !   JA, durch den Arzt bestätigt !   NEIN, ich war deswegen nie beim Arzt 
7. Was wurde vom Arzt als Ursache der Beschwerden  
    beziehungsweise des „Reizdarms“ angenommen? 
 !  frühere Reisen 
 !  Arzt wusste keine Erklärung oder hat keine Ursache genannt 
 !  ich habe keinen Arzt befragt 
 !  ich weiss nicht 
 !  Anderes, was?   _____________________________________________ 
8. Wurde in Ihrer Familie, bei Eltern, Geschwistern oder eigenen Kindern, je ein Reizdarm     
    von einem Arzt festgestellt? 
 !  NEIN   !  JA 
9. Wie anfällig stufen Sie sich in Bezug auf Durchfall ein? 
 !  sehr anfällig  !  mässig anfällig  !  gar nicht anfällig 
10. Haben Sie in den letzten vier Monaten je an Durchfall gelitten? 
 !  JA "  !  NEIN !  weiter zu Frage 15. 
11. Wieviele Stuhlentleerungen hatten Sie maximal pro 24 Stunden? 
  ____  Stuhlentleerungen ! weiss nicht mehr 
12. Wie war dabei die Stuhlkonsistenz vorwiegend?  
 !  wässrig  !  breiig  !  geformt 
13. Hatten Sie zusammen mit dem Durchfall eine oder mehrere der folgenden 
 Beschwerden: 
 !  Fieber   !  Übelkeit  !  Erbrechen   !  Bauchkrämpfe   
 !  plötzlicher Stuhldrang  !  Blut  im Stuhl !  Schleim im Stuhl  
 !  Keine Begleit-Beschwerden 
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14. Wieviele Tage hat der Durchfall insgesamt etwa angedauert? 
 !  etwa      Tage  !  dauert noch an  !  weiss nicht mehr 
15. Haben Sie schon während oder nach einer früheren Reise an „Reisedurchfall“ 
gelitten? 
  !  NEIN !  weiter zu Frage 17.    !  JA     !  weiss nicht mehr 
16. Wie beurteilen Sie den Schweregrad des Reisedurchfalles? 
!  leicht       (ich konnte die geplanten Tätigkeiten immer durchführen) 
!  mittel       (ich konnte nicht alle Tätigkeiten durchführen) 
!  schwer    (ich musste mindestens 12 Stunden zuhause bleiben oder konsultierte einen Arzt) 
17. Wurde je von einem Arzt eine chronische Darmerkrankung festgestellt, z.B. Darmkrebs, 
 entzündliche Darmerkrankung (Morbus Crohn, Colitis ulcerosa), Zöliakie? 
  !  NEIN "   !  JA !  STOP! Wenden Sie sich bitte an das Studienteam 
18. Leiden Sie an einer anderen chronischen Erkrankung? 
   !  NEIN "   !  JA, welche? 
 
!  rheumatischer Formenkreis 18.1 
!  Diabetes mellitus/Zuckerkrankheit 18.2 
!  Herz-, Kreislauf (z.B. Bluthockdruck) 18.3 
!  Venenthrombosen 18.4 
!  Atemwegserkrankung (Asthma she. unten) 18.5 
!  Schilddrüsenerkrankung 18.6 
 (z.B. Morbus Basedow, Kropf) 
!  Gicht 18.7 
!  andere, welche? ________________ 18.8 
19. Leiden Sie an einer allergischen Erkrankung?  
   !  JA    !  NEIN ! weiter zu Frage 21. 
   Wenn JA, an welcher? Mehrfachantworten sind möglich. 
   !  Heuschnupfen 
   !  Atopische Dermatitis oder Neurodermitis 
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   !  Allergisches Asthma 
   !  Bienen- und Wespenstichallergie 
   !  Anderes, was? _______________________________ 
20. Wurde diese allergische Erkrankung durch einen Arzt bestätigt? 
   !  NEIN   !  JA 
21. Haben Sie in den letzten zwölf Monaten ein einschneidendes Ereignis erlebt? (z.B. 
 schwerer Unfall, Todesfall in der engeren Familie, Scheidung, Arbeitsplatz-Verlust) 
   !  NEIN   !  JA, welches?   ____________________ 
22. Stehen Sie im Moment unter Stress / starker Belastung? 
 !  überhaupt nicht !  wenig !  mittelmässig !  stark 
23. Rauchen Sie, wenn auch nur selten (Zigaretten, Zigarren, Cigarillos, Pfeife)? 
   !  NEIN !  JA 
Wenn JA, wie viel rauchen Sie im Durchschnitt? 
 !  weniger als einmal täglich 
 !  einmal täglich !  mehrmals täglich 
24. Haben Sie je regelmässig während mehr als 6 Monaten geraucht? 
   !  NEIN !  JA 
25. Trinken Sie täglich alkoholische Getränke? 
   !  NEIN !  JA 
 Wenn JA, trinken Sie täglich mehr als einen halben Liter Bier oder ein Glas Wein 
 oder ein Glas gebranntes Wasser (wie z.B. Schnaps)? 
 !  NEIN !  JA 
26. In welchem Land wurden Sie geboren  
 oder lebten als Kind während mindestens fünf Jahren? 
 !  CH        !  anderes Land:  _____________________________ 
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27. Welches ist die höchste Ausbildung, die Sie mit einem Diplom oder Zeugnis 
 abgeschlossen haben? 
 !  Obligatorische Schule oder kürzere Schulzeit 
 !  Berufslehre, Berufsschule 
 !  Maturitätsschule, Lehrerseminar, andere allgemeinbildende Schule 
 !  Höhere Berufsausbildung (Meisterdiplom, Eidg. Fachausweis) 
 !  Universität, Hochschule oder Fachhochschule 
 !  Andere Ausbildung, welche?_________________________________________ 
 !  Keine Ausbildung 
28. Wird dies Ihre erste Reise sein: 
           !  in diesen Teil der Erde (Sub-Kontinent) 
           !  in ein tropisches oder subtropisches Land 
!  NEIN 
29. Welches ist Ihre Körpergrösse? __________ cm 
30. Welches ist Ihr Körpergewicht? _________ kg 
HERZLICHEN DANK FÜR IHRE TEILNAHME! 
Bitte geben Sie diesen Bogen der studienverantwortlichen Person ab 
 
Q2A Reisedurchfall unterwegs 
Datum: ID – Nr.  
Bitte auf Reise mitnehmen! Sofern Sie während Ihrer Reise an Durchfall leiden, bitten wir 
Sie, diesen Fragebogen baldmöglichst auszufüllen und uns sobald Sie zurück sind 
zuzusenden. Auch wenn Sie keinen Durchfall während Ihrer Reise hatten, möchten wir Sie 
bitten, die Fragen zu beantworten und uns baldmöglichst mit beiliegendem Antwortcouvert 
zuzusenden. Herzlichen Dank! 
Bitte das zutreffende Feld ! ankreuzen oder hineinschreiben bei ____ . 
1. Sind Sie wie geplant für    ____ Wochen nach _________________________ gereist? 
 !    JA !    NEIN,  
!  ich bin stattdessen für ____ Wochen nach _______________ gereist. 
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 !  ich bin nicht gereist.  !  für Sie ist die Befragung zu Ende, vielen Dank. 
2. Haben Sie unterwegs (oder kurz nach Ihrer Rückkehr) Durchfall erlitten? 
! JA " !  NEIN  ! weiter zu Frage 10. 
3. Wieviele Stuhlentleerungen hatten Sie maximal pro 24 Stunden? 
 ___  Stuhlentleerungen  
2.1. Haben Sie während (oder kurz nach) Ihrer Reise mehrere Durchfallerkrankungen 
gehabt, wobei jeweils mindestens 3 Tage (mind. 72 h) dazwischen lagen? 
  !  JA, wie viele Male? 
!  zweimal 
!  dreimal 
!  anderes, was? _____________________ 
  !  NEIN, nur einmal Durchfallerkrankung gehabt. 
4. Wie war dabei die Stuhlkonsistenz vorwiegend?  
 !  wässrig      !  breiig  !  geformt 
5. Hatten Sie zusammen mit dem Durchfall eine oder mehrere der folgenden Beschwerden: 
!  Fieber !  Übelkeit !  Erbrechen !  Bauchkrämpfe 
!  plötzlicher 
 Stuhldrang 
!  Blut  im Stuhl !  Schleim im Stuhl !  Keine Begleit-
Beschwerden 
6. Am wievielten Tag nach Ihrer Ankunft am Urlaubsort ist der Durchfall aufgetreten? 
  !  am     . Tag !  in der ___. Woche  !  weiss nicht mehr 
7. Wieviele Tage hat der Durchfall insgesamt etwa angedauert? 
 !  etwa      Tage !  dauert noch an !  weiss nicht mehr 
8. Wie beurteilen Sie den Schweregrad des Durchfalles? 
!  leicht  (ich konnte die geplanten Tätigkeiten immer durchführen) 
!  mittel  (ich konnte nicht alle Pläne durchführen) 
!  schwer    (ich musste mindestens 12 Stunden im Zimmer bleiben oder konsultierte einen Arzt) 
9. Haben Sie wegen des Durchfalls im Ausland: mehrere Antworten möglich 
  !  Medikamente in einer Apotheke vor Ort besorgt? 
  !  einen Arzt konsultiert? Falls JA: !  in der Praxis 
!  im Spital (mindestens eine Nacht) 
!  einen bekannten Arzt, z.B. in der Reisegruppe 
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  !  Anderes, was? _____________________________________ 
  !  Arzt nach der Reise konsultiert, Stuhlbefund? : _______________________________ 
10. Haben Sie ein Durchfall-Medikament eingenommen? 
 !  NEIN 
 
!  JA, welches? _________________________________  
wofür? zur Behandlung von Symptomen, nämlich 
 !  durchfallstoppendes Medikament  
 !  Flüssigkeitsersatz (rehydrierende Lösung)  
 !  vorbeugend (präventiv) gegen Durchfall  
 !  weiss nicht mehr 
11. Sind Sie während dieser Reise oder kurz nach Ihrer Rückkehr erkrankt?  
 (Unfälle nicht eingeschlossen) 
 !  NEIN ! weiter zu Frage 12. 
 !  JA, hatten Sie Fieber? !  NEIN  
      !  JA, Temperatur gemessen: ____  °C 
 Sind andere Symptome aufgetreten?  
!  Erkältung (Halsschmerz, Husten) 11.1 
!  Gelenkschmerzen 11.2 
!  Hautausschlag (nicht Sonnenbrand) 11.3 
!  Kopfschmerzen, Schwindel (wegen Höhe) 11.4 
!  Lähmungserscheinungen 11.5 
!  Verstopfung 11.6 
!  anderes, was? ________________________________ 11.7 
12. Haben Sie während Ihrer Reise irgendwelche andere Medikamente eingenommen? 
!  NEIN !  JA,  gegen? _________________________________________ 
 Name?  ____________________ wie lange?____________ 
13. Haben Sie ein Antibiotikum eingenommen? 
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!  NEIN !  JA, welches?  ____________________________ 
wofür? zur Behandlung von Symptomen, nämlich bei 
 !  Durchfall 
 !  andere Magen-Darm-Erkrankungen 
 !  andere Infektionen 
 !  vorbeugend (präventiv) gegen Durchfall 
 !  weiss nicht mehr 
14. Folgten Sie der Empfehlung „cook it, boil it, peel it or forget it“  
 (koch es, schäl es oder vergiss es!)? 
 !  JA !  NEIN  !  ich kenne die Empfehlung nicht 
15. Wo haben Sie sich verpflegt? mehrere Antworten möglich 
 ! privat (z.B. bei einer Familie, selber gekocht) 
 ! am Buffet in Hotels, Restaurants 
 ! bei Strassenverkäufern 
16. Haben Sie Leitungswasser getrunken? 
 !  NEIN !  JA  
17. War die medizinische Reiseberatung für Sie von Nutzen? 
 !  sehr nützlich  !  mässig nützlich  !  gar nicht nützlich 
Was haben Sie an der Beratung vermisst? 
 
HERZLICHEN DANK FÜR IHRE TEILNAHME!  
Bitte in beiliegendem Couvert zurücksenden 
 
Wir melden uns bei Ihnen für die Studie in 6 Monaten dann automatisch wieder. 
Teilen Sie uns bitte mit, sollten sich Ihre Adressdaten ändern. 
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Q3 Ihr Befinden 6 Monate nach der Reise            Datum:                    ID-Nr.: 
1. Haben Sie während der letzten 6 Monate ein zweites Mal ein tropisches oder  
 subtropisches Land oder ein Entwicklungsland besucht?  
!  NEIN 
  !  JA, wann (Datum)?  Von: ________________ bis: _________________ 
  Reiseziel(e)?  _______  Wie lange dauerte die Reise?  ______  Wochen 
2. Litten Sie während der vergangenen 6 Monate nach Ihrer Rückkehr an Durchfall?
 Mehrfachantworten möglich 
  !  NEIN !  JA, wann? 
     !  während der unter 1. erwähnten Reise, wie lange? ___ 
Tage  
 !  zu Hause, wann? __ / __ / __, wie lange? ___ Tage 
 !  anderes, was? _________________ 
3. Litten Sie in den vergangenen 3 Monaten an mindestens zwei Tagen pro 
Monat d.h. wiederholt an Unwohlsein oder Schmerzen am Unterbauch?  
(Menstruationsbeschwerden ausgenommen) 
  !  NEIN 
   !  weiter zu Frage 11. 
!  JA, mehrere Antworten möglich: 
 !  JA, im 1. bis 3. Monat nach der ersten Reise 
 !  JA, im 4. bis 6. Monat nach der ersten Reise 
4. Besserten sich das Unwohlsein oder die Schmerzen nach dem Stuhlgang  
   oder hörten Sie ganz auf? 
   !  NEIN  !  JA 
5. Als das Unwohlsein oder die Schmerzen begonnen haben, hatten Sie selteneren  
  Stuhlgang? 
    !  NEIN   !  JA 
6. Als das Unwohlsein oder die Schmerzen begonnen haben, hatten Sie häufigeren  
  Stuhlgang? 




Dissertation Raffaela Laura Pitzurra 
 
7. Als das Unwohlsein oder die Schmerzen begonnen haben, hatten Sie eher 
weicheren Stuhl festgestellt als üblicherweise? 
    !  NEIN   !  JA 
8. Als das Unwohlsein oder die Schmerzen begonnen haben, hatten Sie eher härteren 
Stuhl festgestellt als üblicherweise? 
    !  NEIN   !  JA 
9. Traten in den vergangenen 6 Monaten während mindestens 6 Wochen (mindestens 
2 bis 3 mal pro Monat) eines der folgenden Symptome auf?   
Bitte alles Zutreffende ankreuzen. 
 !  Stuhlgang weniger als dreimal pro Woche 
  !  harter oder klumpiger Stuhl     
  !  Krämpfe während des Stuhlganges 
  !  Gefühl einer unvollständigen Entleerung nach dem Stuhlgang 
  !  Ein Gefühl, dass der Stuhl während des Stuhlganges blockiert ist 
  !  Ein Bedürfnis mit Druck, eine vollständige Stuhlentleerung erreichen zu müssen 
  !  wässriger, ungeformter oder breiartiger Stuhl 
  !  Stuhlgang häufiger als dreimal pro TAG (4 mal und mehr) 
  !  Völlegefühl, Blähung oder Anschwellen 
10. Wie häufig traten in den vergangenen 3 Monaten  
 
nie oder 





  •  harter oder klumpiger Stuhl auf? ! ! ! ! ! 
  •  ungeformter, wässriger oder 
     breiartiger Stuhl auf? 
! ! ! ! ! 
11. Traten in den vergangenen 6 Monaten während mindestens 6 Wochen (mindestens 
an einem Tag pro Woche) Unwohlsein oder Schmerzen im Bauch oberhalb des 
 Bauchnabels (aber nicht in der Brust) auf? 
   !  NEIN !  weiter zu Frage 13.   !  JA 
12. Besserten sich das Unwohlsein oder die Schmerzen im Bauch oberhalb des  
  Bauchnabels (aber nicht in der Brust) nach der Stuhlentleerung? 
   !  NEIN   !  JA 
13. Haben Sie wegen der oben genannten Beschwerden je irgendwelche Medikamente 
  eingenommen? 
   !  NEIN   
   !  JA, gegen?__________ Name? ________________ wie lange?_______ 
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14. Haben Sie wegen der oben genannten Beschwerden je einen Arzt aufgesucht? 
   !  NEIN !  Ende der Befragung, vielen Dank! 
   !  JA, welches war sein Befund? ____________________________ 
15. Dürfen wir den Arzt kontaktieren - ausschliesslich zur Diagnose des Reizdarmes 
  
   !  NEIN  !  JA:  Name, Vorname:    ___________________ 
      Strasse:   ___________________  
      Postleitzahl, Ort:  ______   ____________ 
      Telefon:   ____________________ 
HERZLICHEN DANK FÜR IHRE TEILNAHME! 
    Bitte in beiliegendem Couvert zurücksenden 
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